Increased circulating fibronectin, depletion of natural IgM and heightened EBV, HSV-1 reactivation in ME/CFS and long COVID

- 3
- 4

Zheng Liu¹, Claudia Hollmann¹, Sharada Kalanidhi², Arnhild Grothey¹, Sam Keating¹, Irene 5 Mena-Palomo¹⁴, Stephanie Lamer³, Andreas Schlosser³, Agnes Kaiping¹, Carsten Scheller¹, 6 Franzeska Sotzny⁴, Anna Horn⁵, Carolin Nürnberger⁵, Vladimir Cejka⁶, Boshra Afshar¹, 7 Thomas Bahmer⁷, Stefan Schreiber⁷, Jörg Janne Vehreschild⁸, Olga Miljukov⁵, Christian 8 Schäfer⁹, Luzie Kretzler¹⁰, Thomas Keil¹⁰, Jens-Peter Reese⁵, Felizitas A Eichner⁵, Lena 9 Schmidbauer⁵, Peter U Heuschmann^{5,14,15}, Stefan Störk⁶, Caroline Morbach⁶, Gabriela 10 Riemekasten¹¹, Niklas Beversdorf¹, Carmen Scheibenbogen⁴, Robert K Naviaux¹², Marshall 11 Williams¹³, Maria E Ariza^{13#}, Bhupesh K Prusty^{1#} 12

13

```
14
```

¹Institute for Virology and Immunobiology, Julius-Maximilians-University of Würzburg,
 Würzburg, Germany

²Stanford Genome Technology Center, Stanford University School of Medicine, Stanford, CA,
 USA

³Rudolf Virchow Center, Center for Translational Bioimaging, Julius-Maximilians-University of

20 Würzburg, Germany

⁴Institute for Medical Immunology, Charité-Universitätsmedizin Berlin, Berlin, Germany

^{22 5}Institute of Clinical Epidemiology and Biometry, Julius-Maximilians-University of Würzburg,

23 Würzburg, Germany.

- ⁶Department of Clinical Research & Epidemiology, Comprehensive Heart Failure Center and
- 25 Department of Medicine I, University Hospital Würzburg, Würzburg, Germany

²⁶ ⁷Internal Medicine Department I, University Hospital Schleswig-Holstein UKSH - Campus Kiel,

27 Kiel, Germany

⁸University of Cologne, Faculty of Medicine and University Hospital Cologne, Department of

29 Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf,

30 Germany

⁹University Medicine Greifswald, Institute of Clinical Chemistry and Laboratory Medicine,

32 Greifswald, Germany

33	¹⁰ Charité - Universitätsmedizin Berlin and Berlin Institute of Health (BIH), Berlin, Germany	
34	¹¹ Klinik für Rheumatologie, Universitätsklinikum Schleswig-Holstein, Lübeck	
35	¹² Departments of Medicine, Pediatrics, and Pathology, University of California, San Diego	
36	School of Medicine, San Diego, USA	
37	¹³ Institute for Behavioral Medicine Research (IBMR), The Ohio State University, Columbus,	
38	Ohio, USA	
39	¹⁴ Institute for Medical Data Sciences, University Hospital Würzburg, Würzburg	
40	¹⁵ Clinical Trial Center, University Hospital Würzburg, Würzburg	
41 42 43 44 45 46		
47	# Co-senior authors	
48 49 50 51	Please send correspondence to: <u>bhupesh.prusty@uni-wuerzburg.de;</u> maria.ariza@osumc.edu	
52 53	Key words: ME/CFS, long COVID, (n)IgM, Fibronectin, EBV, HSV-1, HHV-6, dUTPase	
54		
55		

56 Summary

57 Myalgic Encephalomyelitis/ Chronic Fatigue syndrome (ME/CFS) is a complex, debilitating, 58 long-term illness without a diagnostic biomarker. ME/CFS patients share overlapping 59 symptoms with long COVID patients, an observation which has strengthened the infectious 60 origin hypothesis of ME/CFS. However, the exact sequence of events leading to disease 61 development is largely unknown for both clinical conditions. Here we show antibody 62 response to herpesvirus dUTPases, particularly to that of Epstein-Barr virus (EBV) and HSV-1, 63 increased circulating fibronectin (FN1) levels in serum and depletion of natural IgM against 64 fibronectin ((n)IgM-FN1) are common factors for both severe ME/CFS and long COVID. We 65 provide evidence for herpesvirus dUTPases-mediated alterations in host cell cytoskeleton, 66 mitochondrial dysfunction and OXPHOS. Our data show altered active immune complexes, 67 immunoglobulin-mediated mitochondrial fragmentation as well as adaptive IgM production 68 in ME/CFS patients. Our findings provide mechanistic insight into both ME/CFS and long 69 COVID development. Finding of increased circulating FN1 and depletion of (n)lgM-FN1 as a 70 biomarker for the severity of both ME/CFS and long COVID has an immediate implication in 71 diagnostics and development of treatment modalities.

72

73

74 Main Text

75 Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) is considered as a chronic 76 post viral illness that shares several overlapping clinical symptoms with long COVID or postacute sequelae of SARS-CoV-2 infection (PASC)¹ including neurological disturbances, extreme 77 78 fatigue, post-exertional malaise (PEM), and postural orthostatic tachycardia syndrome 79 (POTS). Immune dysregulation, microbiota dysbiosis, autoimmunity, vascular dysfunction, 80 dysfunctional neurological signaling are some of the key hypothesized mechanisms for both the diseases¹. However, there are no diagnostic biomarkers for the disease diagnosis and no 81 82 treatment modalities yet. The infectious origin hypothesis of ME/CFS is long postulated and 83 is supported by development of long COVID after SARS-CoV-2 infection. Our laboratories 84 have postulated the idea of herpesvirus reactivation as a key mechanism of both ME/CFS as well as long COVID development, which is now corroborated by several groups^{2,3}. In this 85 86 paper, we provide evidence for frequent HSV-1 and EBV reactivation in both ME/CFS and 87 long COVID patients and provide an experimental reasoning for potential cellular damage 88 through herpesvirus dUTPase proteins. Furthermore, we show that ME/CFS patients have 89 altered autoimmune features, which possibly developed because of depletion of natural IgM 90 ((n)IgM) within primary hematopoietic organs. Our study further focuses on fibronectin 91 protein that shows altered expression and immune response patterns that correlates with 92 disease severity.

- 93
- 94
- 95
- 96
- 97 98
- 99
- 100
- 101

102

- ±02
- 103
- 104
- 105

106

107 **Results**

108 Increased HSV-1 and EBV reactivation in ME/CFS and long COVID

109 Reactivation of different herpesviruses including HHV-6, HHV-7 and EBV is frequently associated with ME/CFS development^{4,5}. Most recently, reactivation of several herpesviruses 110 including EBV was detected during acute SARS-CoV-2 infection². To test the possibility that 111 112 these dormant viruses are being reactivated in long COVID patients and are producing 113 dUTPases, we examined the humoral response against the viral dUTPases of EBV, HHV-6 and 114 HSV-1 in a cohort of patients (n=278) at least after 6 months of first SARS-CoV-2 infection (COVIDOM cohort⁶). Only 6% of the patients of this cohort were hospitalized during the 115 116 acute SARS-CoV-2 infection while rest of the 94% of the patients had mild to moderate SARS-CoV-2 infection without the need for hospitalization⁷. This patient cohort was further 117 divided into three groups based on a scoring system⁶, which separated mild and severe long 118 COVID patients (mild (n=107) and severe LC (n=22) respectively) from those who did not 119 120 show any major health issues post SARS-CoV-2 infection and recovery (No LC, n=149). 121 Distribution of these patient and control groups according to their age and gender is shown 122 in Extended Fig. 1a (Supplementary Table 1). The long COVID cohort were compared to healthy blood donors (HC, n=31) and ME/CFS patients (ME/CFS, n=77). As commercial 123 124 dUTPase ELISA based assay is not available, we used purified recombinant dUTPase proteins 125 as a bait to capture human IgG in Western blots (Fig. 1a). Our results showed heightened IgG 126 responses against EBV and HSV-1 dUTPases in ME/CFS and long COVID patients (Fig. 1b, 127 Extended Fig. 1b). Strikingly higher IgG response to HSV-1 dUTPase was detected in mild and 128 severe long COVID patients (Fig. 1b). A modest but significant increase in IgG response 129 against HHV-6 dUTPase was observed in ME/CFS patients (Fig. 1b, Extended Fig. 1) but not in 130 the cohorts of SARS-CoV-2 infected patients, which had decreased IgG response against 131 HHV-6 dUTPase in comparison to healthy controls. These results suggest an overall increase 132 in EBV and HSV-1 reactivation in both ME/CFS and SARS-CoV-2 infected patients.

133

134 Herpesvirus dUTPase proteins alters mitochondrial architecture

The increased anti-dUTPase IgG response observed in patient cohorts after 6 months of first
 SARS-CoV-2 infection suggests EBV and HSV-1 reactivation potentially contributing to

disease development. Studies by our group have shown that the herpesviruses dUTPases
 represent a new family of Pathogen Associated Molecular Patterns (PAMPs)⁷ protein ligands
 with novel immune and neuromodulatory properties, independent of the enzymatic activity.
 Hence, we further explored the potential role of these viral proteins in human biology.

141 Transient expression of HSV-1, HHV-6 and EBV dUTPase in cultured human cells induced a 142 hyperpolarized and hyperfused mitochondrial phenotype (Fig. 1c, Extended Fig. 2a) with 143 increased mitochondrial surface area (Fig. 1d, Extended Fig. 2b). The appearance was similar 144 to the stress-induced mitochondrial hyperfusion (SIMH) phenotype that is seen with exposure to certain environmental chemicals⁸, nutrient depletion, viral infections, and in 145 certain chronic disease states⁹. In U2-OS cells, all the three dUTPases were predominantly 146 147 localized within the nucleus (Extended Fig. 2a). In HEK293 cells, only EBV dUTPase localized 148 to the nucleus whereas HSV-1 and HHV-6 dUTPases remained mostly within cytoplasm (Fig. 1c). EBV dUTPase (BLLF3) is known to be localized within nucleus¹⁰ whereas HSV-1 dUTPase 149 150 (UL50) is reported to be localized within both cytoplasm and nucleus. Irrespective of the 151 protein localization, mitochondrial fusion protein Mfn1 was upregulated by all the three viral 152 dUTPases (Fig. 1e). Other mitochondrial fusion proteins like Mfn2, Miga1, remained 153 unchanged (Extended Fig. 2c). Mitophagy was inhibited to various degree by all the three 154 dUTPases, EBV dUTPase being the most efficient in decreasing LC3 β protein expression (Fig. 155 1e). Tetramethylrhodamine ethyl ester (TMRE) staining of dUTPase transfected cells in the 156 presence of ATP synthase inhibitor, oligomycin showed a decrease in mitochondrial 157 membrane potential in cells expressing EBV dUTPase (Fig. 1f) suggesting poor mitochondrial 158 health and energetics particularly in presence of EBV dUTPase. HSV-1 and HHV-6 dUTPase 159 did not show any significant effect (Extended Fig. 2d). EBV dUTPase expressing cells showed 160 characteristics of hyperpolarized mitochondria with higher mitochondrial membrane potential in comparison to mock vector transfected cells in the absence of oligomycin 161 162 (Extended Fig. 2e). On the other hand, exposing U2-OS cells in culture to recombinant EBV 163 dUTPase induced Drp-1 dependent mitochondrial fragmentation and appearance of spherical hyperpolarized mitochondria (Extended Fig. 2f-g) in a dose dependent manner that 164 165 showed increased mitochondrial membrane potential under normal growth conditions, 166 which decreased in presence of oligomycin suggesting poor mitochondrial health (Extended Fig. 2h). Such spherical mitochondrial phenotype was previously described as 'mitosphere' 167 that induces oxidative stress¹¹. We constitutively expressed all the three viral dUTPases and 168

169 immunoprecipitated viral dUTPase proteins in HEK293 cells (Extended Fig. 2i). Mass 170 spectrometry analysis of co-immunoprecipitated proteins showed enrichment of several 171 cellular cytoskeleton associated proteins including neurofilament medium chain (NEFM), epiplakin 1 (EPPK1), plectin (PLEC) (Fig. 1g-h, Extended Fig. 2i-k) suggesting strong 172 173 association of host cell cytoskeleton with herpesvirus dUTPases. Cellular localization of 174 dUTPase proteins seems to be not associated with its interaction with cell cytoskeleton as 175 both HSV-1 dUTPase and EBV dUTPase showed similar interacting partners. We further 176 validated some of the interacting partners of EBV and HSV-1 dUTPases identified by mass 177 spectrometry through immunoblotting (Fig. 1h, Extended Fig. 2l). These results suggest that 178 herpesvirus dUTPases interact with host cell cytoskeleton and alter mitochondrial 179 architecture as well as function.

180

181 Immunoglobulins and mitochondrial fragmentation in ME/CFS

Chronic, recurrent HSV-1 and EBV infections lead to development of autoimmunity^{12,13}. We 182 hypothesized that autoimmunity-induced antibodies in serum might induce mitochondrial 183 dysfunction as shown by others^{14,15}. To check if immunoglobulins (Igs) isolated from ME/CFS 184 patients can induce mitochondrial alterations in vitro, we purified Ig fractions from ME/CFS 185 186 patients (n=17) and healthy controls (n=13) using Sepharose G columns. Exposure of as low 187 as 1 µg of purified immunoglobulins from severe ME/CFS patients fragmented mitochondria 188 within 12 h of exposure (Fig. 2a-b). The mitochondrial fragmentation phenotype for severe 189 ME/CFS patients was cell-type dependent and was pronounced in primary human umbilical 190 vein endothelial cells (HUVEC) (Fig. 2a-b). Ig from healthy controls showed a mixed effect on 191 mitochondrial architecture whereas Ig from mild/moderate ME/CFS patients had a modest 192 but significant effect on mitochondria in HUVEC cells. Fragmented mitochondrial phenotype 193 by Ig from severe ME/CFS patients showed decreased Mfn1 and PLD6 protein levels (Fig. 2c). 194 Efficiency of IgG purification was tested by analyzing antibodies against EBV dUTPase in EBV 195 positive and negative patient serum, which showed enriched EBV dUTPase antibodies after 196 purification (Extended Fig. 3a, b).

197 Purified IgG from human serum mostly contains immunoglobulin fractions with freely 198 available Fc receptors along with associated immune complex proteins. These immune 199 complex proteins can also potentially be a factor that can induce mitochondrial 200 fragmentation. Hence, we analyzed the same purified IgG fractions from healthy control (n=12) and ME/CFS patients (n=15), that were used in mitochondrial studies, by mass spectrometry. IgG and IgM bound immune complex purification was of high quality and uniform throughout the samples as validated by similar enrichment of complement components in all the samples (Extended Fig. 3c). Only three cellular proteins showed decreased amounts within the immune complex of ME/CFS patient groups in comparison to healthy controls (Fig. 2d, Extended Fig. 3d), i.e, fibronectin (FN1), alpha2 macroglobulin (A2M) and serotransferrin (TF).

208 In an independent microarray study, we also detected IgM against fibronectin antigen as one 209 of the few IgMs that were selectively decreased in severe ME/CFS patients. To test potential 210 IgM response against selective autoantigens frequently involved in autoimmune diseases, 211 IgM levels were tested against 120 autoantigens (Supplementary Table 2) in a small cohort 212 of mild to severe ME/CFS patients (n=12) and healthy controls (n=3). Samples were blinded 213 throughout the experimental procedure and data analysis. Multivariate clustering of log-214 transformed data resulted in the observation that patients could be separated into distinct 215 groups comprising healthy, mild/moderate and severe patients (Fig. 2e) on the basis of IgM 216 antibody levels against autoantigens like PCNA, collagen V and VI, complement C3, CRP etc. 217 (Fig. 2f, Extended Fig. 4a-b). IgM against fibronectin was one of the 10 variables that 218 contributed to these clustering. These results suggest that decreased immunoglobulin 219 against fibronectin and other proteins are key features of severe ME/CFS.

220

221 ME/CFS and long COVID patients show increased amounts of circulating fibronectin

222 FN1 interacts with circulating immune complex and aggregates with IgG, IgM and IgA 223 thereby playing a significant role in both the clearance of activated immune complexes and tissue deposition of fibronectin-containing immune complexes in several diseases¹⁶. Lack of 224 225 fibronectin within immune complexes and their potential accumulation within blood can 226 indicate lack of protection against certain pathogenic infections. To check if overall 227 fibronectin protein expression is downregulated in ME/CFS or is specifically removed from 228 immune complexes for some reason, we measured circulating fibronectin levels in serum of 229 ME/CFS (n=66) patients and healthy controls (n=63). Circulating fibronectin levels were 230 significantly higher in ME/CFS patients in comparison to healthy controls as shown in the 231 Kernel Density plot (Fig. 2g-h). Serum FN1 levels showed a positive correlation with ME/CFS 232 severity as patients with bell scores of 0-20 had significantly higher FN1 levels (Fig. 2i, HC vs

Bell 0-20, ****P < 0.0001. Bell 0-20 vs Bell 30-50, **P = 0.0032) in serum than those with 233 234 bell score between 30-50 (Area under the receiver operator characteristic (AUROC) = 79.8% 235 for severe ME/CFS (Fig. 2j), P<0.0001). We further compared circulating fibronectin levels 236 within SARS-CoV-2 positive cohorts. Only long COVID patients (both mild and severe) showed significantly higher circulating fibronectin levels (Fig. 2k, HC vs mild LC, **P = 237 0.0032. HC vs severe LC, *P = 0.0488) in comparison to healthy controls and SARS-CoV-2 238 239 positive but without long COVID individuals (No LC). Circulating fibronectin contains the 240 majority of plasma fibronectin (pIFN1) secreted by hepatocytes and a minor fraction of 241 cellular fibronectin (clFN1) secreted by other cell types. We compared circulating FN1 242 composition between some of the ME/CFS patients to that of healthy controls, which 243 showed an overall increase in both extra domain A (EDA) negative pIFN1 as well as EDA 244 domain and cell binding domain (CBD) positive clFN1 in ME/CFS patients (Extended Fig. 5a) 245 suggesting an overall increase in circulating fibronectin levels. Total human IgG was used as 246 loading control. Interestingly, we observed significant differences in circulating fibronectin 247 levels between male and females (Extended Fig. 5b). Particularly, healthy controls and SARS-248 CoV-2 positive but no long COVID (no LC) groups showed significantly higher FN1 levels in 249 females than males (Extended Fig. 5b, HC male vs female, **P = 0.0014; No LC male vs 250 female, *P = 0.0204; severe LC male vs female, *P = 0.0347). Similarly, increasing FN1 levels 251 among female long COVID patients showed positive correlation with disease severity (Extended Fig. 5c, HC male vs ME/CFS male, ***P = 0.0001; HC male vs mild LC male, *P = 252 0.012; HC female vs no LC female, *P = 0.0193; HC female vs mild LC female, ***P = 0.0006; 253 HC female vs severe LC female, **P = 0.0016), which was less among male long COVID 254 255 patients. However, because of the comparatively low levels of circulating FN1 among healthy 256 males, male ME/CFS patients showed a significant increase in FN1 levels (Extended Fig. 5c). 257 In summary, our results show increased circulating FN1 levels in ME/CFS and long COVID 258 patients that correlates with disease severity.

259

260 **Depletion of IgM against FN1 correlates with disease severity**

One of the interesting observations from our antibody microarray studies was the decrease in IgM antibodies against FN1 among some of the severe ME/CFS patients (Fig. 2a, Extended Fig. 5d). Antibodies (IgG, IgM and IgA) against FN1 are frequently detected in plasma of healthy individuals¹⁷. Moreover, all the three forms of immunoglobulins can bind to the

same region of the FN1 protein¹⁶. An inverse correlation between increasing circulating FN1 265 266 levels and decreased IgM responses against FN1 were previously documented during Trypanosoma infection¹⁸. Hence, we argued that IgM against FN1 possibly belongs to the 267 268 natural IgM ((n)IgM) category. Natural IgM are key immunoglobulins produced specifically by plasma B1 B cells¹⁹ and have important scavenger and protector function²⁰. Decreased 269 (n)IgM can be the source for autoimmunity¹⁹. As a proof of concept, we validated the 270 271 microarray results using immunoblotting with purified human pIFN1 and recombinant FN1.2 272 proteins as a bait, in 7 severe ME/CFS, 5 long COVID and 5 healthy controls, which confirmed 273 the microarray data showing undetectable or poorly detectable amounts of IgM-FN1 274 (Extended Fig. 5e) in severe ME/CFS and long COVID patients. IgM-FN1 was detectable in 275 healthy controls. It is noteworthy that human IgM detected only the full-length pIFN1. For a 276 quantitative analysis, we further developed sandwich ELISA assays to measure serum IgM 277 and IgG levels against human FN1 and measured both in healthy controls (n=63), ME/CFS 278 (n=66) and three different groups of SARS-CoV-2 positive patients (no LC, n=55; mild LC, 279 n=63; severe LC, n=22). The total IgM-FN1 levels were not different between healthy 280 controls and ME/CFS patients (Fig. 3a). However, SARS CoV-2 positive patients showed 281 significantly decreased IgM-FN1 levels in comparison to both healthy controls and ME/CFS patients (Fig. 3a, HC vs No LC, HC vs mild LC, HC vs severe LC, ****P < 0.00001. No LC vs 282 283 severe LC, *P = 0.0376). Furthermore, IgM-FN1 amounts correlated with long COVID severity 284 with the strongest decrease in severe LC patients (Fig. 3a). Similarly, IgG against FN1 was also 285 significantly decreased in all the three groups of SARS-CoV-2 positive patients (Fig. 3b, HC vs No LC, HC vs mild LC, HC vs severe LC, ****P < 0.00001). Severe LC patients showed a trend 286 towards recovery of IgG-FN1 levels. Further separation of ME/CFS patients based on disease 287 288 severity (Bell score), showed significantly decreased IgM-FN1 levels only in severe patients 289 with a Bell score between 0-20 (Fig. 3c, HC vs Bell 0-20, **P = 0.0046. Bell 0-20 vs Bell 30-50, 290 ***P = 0.0002). IgG-FN1 did not show any association with ME/CFS disease severity (Fig. 3d). 291 To answer whether specifically (n)IgM against fibronectin was depleted post SARS-CoV-2 292 infection or not, we tested two of the most common (n)IgMs against phosphoryl choline (PC) 293 and Malondialdehyde (MDA) in a small cohort of healthy controls and all the three groups of 294 SARS-CoV-2 positive patients (n=20 for each group). Both IgM-PC and IgM-MDA levels 295 showed a significant correlation with long COVID severity (Fig. 3e-f, Extended Fig. 6a-b) 296 being the lowest in severe LC patients. AUROC analysis of IgM-FN1 also showed increased

297 detection accuracy as the severity of long COVID increased from no LC to severe LC (Fig. 3g-298 i). Muti-variate ROC analysis using both circulating FN1 and IgM-FN1 levels showed that both 299 these proteins together can potentially serve as a biomarker for severe ME/CFS (Fig. 4a, 300 accuracy of 83.7%) and severe long COVID (Fig. 4b, accuracy of 85.3%). Multiple logistic 301 regression analysis separated healthy controls from severe ME/CFS patients based on both 302 FN1 and IgM-FN1 levels with 83.7% accuracy (Fig. 4c) and healthy controls from both mild 303 and severe long COVID patients with 83.3% accuracy (Fig. 4d). Moreover, both ME/CFS and 304 long COVID patients showed close similarity in terms of their FN1 and IgM-FN1 amounts 305 (Fig. 4e). In fact, severe groups of both ME/CFS and long COVID patients closely resembled 306 each other (Fig. 4f). Interestingly, all the three natural IgMs, i.e., (n)IgM-FN1, (n)IgM-PC and 307 (n)IgM-MDA levels showed a trend towards being more abundant in healthy females than 308 males (Extended Fig. 7a-b). In fact, female ME/CFS patients showed a significant decrease in 309 IgM-FN1 than male patients (Extended Fig. 7a) which was insignificant among other patient 310 groups. All the natural IgM levels were significantly lower in all three groups of LC patients 311 (Extended Fig. 7c) in comparison to healthy controls and had no clear association with 312 gender. In summary, our results show strong depletion of (n)IgMs following SARS-CoV-2 313 infection even after 6 months post-virus infection. Significantly increased circulating 314 fibronectin levels together with the decreased (n)IgM response against fibronectin has the 315 potential to separate SARS-CoV-2 infected non-long COVID individuals from long COVID and 316 severe ME/CFS patients.

317

318 Discussion

319 Chronic post viral illnesses like ME/CFS and long COVID affect multiple body systems and 320 may lead to development of overlapping clinical features with other known health 321 conditions making the diagnosis and treatment difficult for clinicians. No biomarker has been identified for either of the conditions to date¹. Our study found increased humoral 322 323 response against HSV-1, HHV-6 and EBV dUTPases in ME/CFS patients and the same against 324 HSV-1 and EBV in long COVID patients suggesting herpesvirus reactivation as a potential 325 contributor to both the clinical conditions. These results support our previous studies in ME/CFS patients²¹ and corroborate findings from other labs³ showing frequent EBV 326 327 reactivation post COVID-19 infection. Chronic herpesvirus infection contributes to

autoimmunity^{12,13}. Heightened expression of EBV dUTPase protein in plasma cell aggregates 328 329 near glomeruli was shown in kidney biopsy tissue from lupus nephritis (LN) patients (class III 330 and IV) undergoing flares that also exhibit an enrichment of long-lived autoantibody producing memory plasma cells in the kidneys²², which are believed to contribute to disease 331 332 pathogenesis. Interestingly, the terminal differentiation of memory B-cells into plasma cells causes reactivation of latent EBV resulting in the expression of the dUTPase^{23,24}. The 333 334 TLR2/MyD88/miRNA155/Ets-1 pathway is required to produce autoantibodies that form DNA-containing immune complexes (IgG anti-ssDNA, IgG anti-dsDNA)²⁵ and EBV dUTPase is 335 336 a potent activator of TLR2/MyD88 signaling and inducer of pro-inflammatory cytokines and 337 miR155. In some ME/CFS patients exhibiting a dysfunctional GC Ab response, EBV dUTPase 338 may contribute to this process by stimulating an extrafollicular Ab response that promotes 339 increased splenic iNKTFH and marginal zone B cells, which could result in the formation of autoreactive B cells and, subsequently, the production of autoreactive Abs²⁶. Interestingly, 340 341 the dUTPase protein is also released in exosomes from EBV-infected B cells (plasma cells) 342 during abortive lytic replication of EBV and these dUTPase-containing exosomes induced the 343 production of pro-inflammatory cytokines in dendritic cells and PBMCs by engaging TLR2²⁷. 344 We argue that herpesvirus dUTPases post virus reactivation can play a contributing role in 345 disease development. We have recently shown presence of EBV dUTPase proteins within 346 brain biopsies of ME/CFS patients⁵ supporting the notion that strong neurological symptoms of ME/CFS potentially can be due to herpesviruses like HHV-6, EBV reactivating within 347 specific tissues²⁸. However, nearly uniform levels of depletion of IgM-FN1 and IgG-FN1 in all 348 the SARS-CoV-2 positive patients studied suggest that herpesvirus reactivation alone can't 349 350 be responsible for the disease development. At the same time, a decrease in the IgG 351 response against HHV-6 dUTPase in long COVID patients (Fig. 1b) could suggest alterations in 352 the B cell response against specific pathogenic antigens post SARS-CoV-2 infection. We argue 353 that ME/CFS and long COVID are post viral illnesses where the origin of the disease and 354 acute post-infectious clinical features are potentially different. But both the diseases seem 355 to overlap with each other sharing similar secondary chronic clinical features (Extended Fig. 356 8).

357

Endothelial cell dysfunction is a key clinical feature of both ME/CFS²⁹ and long COVID³⁰. In this study, immunoglobulins isolated from severe ME/CFS patients induced alterations in

360 mitochondrial morphology of cultured primary cells favoring a fragmented mitochondrial 361 phenotype. Further proteomic characterization of isolated immunoglobulins and associated 362 circulating immune complexes (CIC) revealed decreased presence of three proteins within 363 the IgG-bound CIC (namely TF, A2M and FN1), FN1 levels showing the clearest differences to 364 that from healthy individuals. On the other hand, circulating FN1 was significantly increased 365 in serum of ME/CFS patients. Atherosclerosis associated inflammation shows deposition of fibronectin in endothelial cells³¹. Antigens that bind to mesangial fibronectin induce 366 glomerulonephritis through immune complex formations³². Plasma fibronectin is targeted by 367 several bacteria including Borrellia burgdorferi³³ and S. aureus³⁴ for cell colonization. On the 368 369 other hand, antibody response develops against plasma fibronectin specifically bound to early Borrelia antigen RevA³⁵. Fibronectin is an essential component of circulating immune 370 $complexes^{36}$ because of its interaction with complement proteins like C1g³⁷ and C3 that 371 protect against pathogenic infections³⁸. Hence, our finding of decreased fibronectin within 372 373 immune complexes of ME/CFS patients could suggest poor bacterial and other pathogen 374 clearance. Significantly increased circulating fibronectin in ME/CFS and long COVID patients 375 was positively correlated with disease severity. Circulating fibronectin binds to TLR4 and induces an inflammatory cytokine response³⁹. Specific domains of fibronectin also activate 376 platelets⁴⁰ and mast cells⁴¹. Increased serum/plasma fibronectin is commonly detected in 377 rheumatic diseases³⁶ and is suggested to be the cause of polyclonal activation of B cells⁴². 378 379 Interestingly, irrespective of disease groups, female patients showed significantly increased 380 circulating FN1 protein levels compared to male patients (Extended Fig. 5b) suggesting a 381 possibility to reach the pathological threshold sooner than males. Increased circulating 382 fibronectin levels are correlated with low levels of IgM against fibronectin during Trypanosoma infection¹⁸. Using different experimental approaches, we showed depletion of 383 IgM against fibronectin as a characteristic feature of severe ME/CFS and long COVID 384 385 suggesting depletion of IgM-FN1 as a key contributor to disease severity.

386

Natural IgM are critical players in maintaining cellular homeostasis through their scavenger, protector, and regulator function^{20,43}. Protection against cellular debris that can cause development of autoimmunity is a key function of (n)IgM. We argue that IgM against fibronectin (IgM-FN1) belongs to the (n)IgM category as IgM-FN1 is frequently detected in plasma of healthy individuals¹⁷. Our results showed presence of abundant IgM against FN1

392 in serum of healthy individuals supporting the notion that IgM-FN1 might belong to the 393 natural IgM category and is crucial in complement activation and protection against 394 autoimmunity. We showed that (n)IgM-FN1 binds only to full-length plasma fibronectin and 395 does not have specificity for cellular fibronectin. As we found decreased fibronectin within 396 the immune complexes of ME/CFS patients, we argue that severe ME/CFS and possibly long 397 COVID patients have compromised complement activation against fibronectin leading to 398 poor pathogen clearance and poor scavenging abilities against apoptotic cells causing 399 generation of a broad range of autoimmune antibodies. Additionally, we noticed a decrease 400 in two of the most common (n)IgMs against PC and MDA in SARS-CoV-2 positive patient 401 cohorts, which strengthens the idea that loss of natural IgMs might be the cause of 402 autoimmunity in both ME/CFS and long COVID patients. Additionally, we observed that 403 females tend to have increased (n)IgM levels than males supporting the idea of immune differences between both genders⁴⁴. These differences in circulating FN1 levels among male 404 405 and female patients as well as gender-dependent differences in (n)IgM levels might explain 406 the predominance of both ME/CFS and long COVID among females compared to males¹.

407 Natural antibodies (IgM, IgG and IgA) are produced by innate-like B cells like B1, B2, and marginal zone (MZ) B cells⁴⁵. (n)IgMs are specifically produced by B1 B cells within bone 408 marrow and other primary lymphoid tissues¹⁹ and by circulating CD20⁺CD38^{hi} B cells⁴⁶. We 409 410 argue that under specific yet to be understood conditions, infection-mediated alterations 411 within primary hematopoietic organs might lead to alterations in B1 B cells (Extended Fig. 8), 412 which can eventually lead to depletion of natural IgM and development of autoimmunity. Measles virus also depletes memory B cells by an unknown mechanism leading to 'immune 413 414 amnesia'⁴⁷. Another potential reason for depletion of (n)IgM can be alterations in $CD4^{+}T$ cells. Non-cognate CD4⁺ T cells, which help plasma B1 cells in mice to generate a unique 415 repertoire of (n) IgM^{48} . Furthermore, CXCR4+ regulatory CD4⁺ T (Treg) cells manipulate both 416 serum IgM levels and (n)IgM production by B1 B cells in the bone marrow⁴⁹. T cell 417 exhaustion and alterations in Treg numbers are documented in ME/CFS⁵⁰. Hence modulation 418 419 of T cell biology within primary hematopoietic tissues can have a potential impact on plasma 420 B1 B cells and (n)IgM levels.

In summary, our findings reveal depletion of (n)IgM to be associated with disease severity in
 ME/CFS and long COVID, which may point to an autoimmune mechanism. Autoimmunity is
 considered as a key causal factor for diseases like ME/CFS. Hence first therapeutic

- 424 interventions have been targeted to deplete pathogenic autoantibodies or B cells. In this
- 425 regard our findings have immediate implications in both ME/CFS and long COVID diagnosis
- 426 and further development of autoantibody treatment.
- 427

428 **References:**

- 429
 1
 Davis, H. E., McCorkell, L., Vogel, J. M. & Topol, E. J. Long COVID: major findings,

 430
 mechanisms and recommendations. Nat Rev Microbiol 21, 133-146,

 431
 doi:10.1038/s41579-022-00846-2 (2023).
- Banko, A., Miljanovic, D. & Cirkovic, A. Systematic review with meta-analysis of active
 herpesvirus infections in patients with COVID-19: Old players on the new field. *Int J Infect Dis* 130, 108-125, doi:10.1016/j.ijid.2023.01.036 (2023).
- 4353Klein, J. et al. Distinguishing features of Long COVID identified through immune436profiling. medRxiv, doi:10.1101/2022.08.09.22278592 (2022).
- 4374Rasa, S. et al. Chronic viral infections in myalgic encephalomyelitis/chronic fatigue438syndrome (ME/CFS). J Transl Med 16, 268, doi:10.1186/s12967-018-1644-y (2018).
- 439 5 Kasimir, F. *et al.* Tissue specific signature of HHV-6 infection in ME/CFS. *Front Mol* 440 *Biosci* **9**, 1044964, doi:10.3389/fmolb.2022.1044964 (2022).
- Bahmer, T. *et al.* Severity, predictors and clinical correlates of Post-COVID syndrome
 (PCS) in Germany: A prospective, multi-centre, population-based cohort study. *EClinicalMedicine* **51**, 101549, doi:10.1016/j.eclinm.2022.101549 (2022).
- Hartung, T. J. *et al.* Fatigue and cognitive impairment after COVID-19: A prospective
 multicentre study. *EClinicalMedicine* 53, 101651, doi:10.1016/j.eclinm.2022.101651
 (2022).
- 4478Tondera, D. et al. SLP-2 is required for stress-induced mitochondrial hyperfusion. The448EMBO Journal 28, 1589-1600, doi:10.1038/emboj.2009.89 (2009).
- 449 9 Das, R. & Chakrabarti, O. Mitochondrial hyperfusion: a friend or a foe. *Biochem Soc*450 *Trans* 48, 631-644, doi:10.1042/BST20190987 (2020).
- 45110Cai, M. et al. Characterization of the subcellular localization of Epstein-Barr virus452encoded proteins in live cells. Oncotarget **8**, 70006-70034,453doi:10.18632/oncotarget.19549 (2017).
- 45411Menges, S. *et al.* Alpha-synuclein prevents the formation of spherical mitochondria455and apoptosis under oxidative stress. *Sci Rep* 7, 42942, doi:10.1038/srep42942456(2017).
- Houen, G. & Trier, N. H. Epstein-Barr Virus and Systemic Autoimmune Diseases. Front *Immunol* 11, 587380, doi:10.3389/fimmu.2020.587380 (2020).
- 459 13 Zhao, Z. S., Granucci, F., Yeh, L., Schaffer, P. A. & Cantor, H. Molecular mimicry by
 460 herpes simplex virus-type 1: autoimmune disease after viral infection. *Science* 279,
 461 1344-1347, doi:10.1126/science.279.5355.1344 (1998).
- 46214Kadaja, L. et al. IgG from patients with liver diseases inhibit mitochondrial respiration463in permeabilized oxidative muscle cells: impaired function of intracellular energetic464units?Mol465doi:10.1023/b:mcbi.0000009876.23921.e6 (2004).

- 46615Cho, S. et al. Neuromyelitis optica (NMO)-IgG-driven organelle reorganization in467human iPSC-derived astrocytes. FASEB J 35, e21894, doi:10.1096/fj.202100637R468(2021).
- 46916Rostagno, A. A., Frangione, B. & Gold, L. Biochemical studies on the interaction of470fibronectin with Ig. J Immunol 146, 2687-2693 (1991).
- 471 17 Bray, B. A., Osman, M. & Turino, G. M. Evidence that fibronectin-immunoglobulin
 472 complexes occur normally in plasma. *Proc Soc Exp Biol Med* 207, 324-331,
 473 doi:10.3181/00379727-207-43823 (1994).
- Truyens, C., Rivera, M. T., Ouaissi, A. & Carlier, Y. High circulating levels of fibronectin and antibodies against its RGD adhesion site during mouse Trypanosoma cruzi infection: relation to survival. *Exp Parasitol* 80, 499-506, doi:10.1006/expr.1995.1062
 (1995).
- 47819Baumgarth, N. The double life of a B-1 cell: self-reactivity selects for protective479effector functions. Nat Rev Immunol 11, 34-46, doi:10.1038/nri2901 (2011).
- 480 20 Ehrenstein, M. R. & Notley, C. A. The importance of natural IgM: scavenger, protector
 481 and regulator. *Nat Rev Immunol* 10, 778-786, doi:10.1038/nri2849 (2010).
- Halpin, P. *et al.* Myalgic encephalomyelitis/chronic fatigue syndrome and gulf war
 illness patients exhibit increased humoral responses to the herpesviruses-encoded
 dUTPase: Implications in disease pathophysiology. *J Med Virol* 89, 1636-1645,
 doi:10.1002/jmv.24810 (2017).
- Chu, V. T. *et al.* Systemic activation of the immune system induces aberrant BAFF and
 APRIL expression in B cells in patients with systemic lupus erythematosus. *Arthritis Rheum* 60, 2083-2093, doi:10.1002/art.24628 (2009).
- 48923Al Tabaa, Y. *et al.* Functional Epstein-Barr virus reservoir in plasma cells derived from490infected peripheral blood memory B cells. *Blood* **113**, 604-611, doi:10.1182/blood-4912008-02-136903 (2009).
- 49224Laichalk, L. L. & Thorley-Lawson, D. A. Terminal differentiation into plasma cells493initiates the replicative cycle of Epstein-Barr virus in vivo. J Virol 79, 1296-1307,494doi:10.1128/JVI.79.2.1296-1307.2005 (2005).
- Wen, Z. *et al.* Autoantibody induction by DNA-containing immune complexes
 requires HMGB1 with the TLR2/microRNA-155 pathway. *J Immunol* 190, 5411-5422,
 doi:10.4049/jimmunol.1203301 (2013).
- Cox, B. S., Alharshawi, K., Mena-Palomo, I., Lafuse, W. P. & Ariza, M. E. EBV/HHV-6A
 dUTPases contribute to myalgic encephalomyelitis/chronic fatigue syndrome
 pathophysiology by enhancing TFH cell differentiation and extrafollicular activities.
 JCI Insight 7, doi:10.1172/jci.insight.158193 (2022).
- Ariza, M. E., Rivailler, P., Glaser, R., Chen, M. & Williams, M. V. Epstein-Barr virus
 encoded dUTPase containing exosomes modulate innate and adaptive immune
 responses in human dendritic cells and peripheral blood mononuclear cells. *PLoS One* 8, e69827, doi:10.1371/journal.pone.0069827 (2013).
- 50628Lerner, A. M. et al. Antibody to Epstein-Barr virus deoxyuridine triphosphate507nucleotidohydrolase and deoxyribonucleotide polymerase in a chronic fatigue508syndrome subset. PLoS One 7, e47891, doi:10.1371/journal.pone.0047891 (2012).
- 50929Sandvik, M. K. et al. Endothelial dysfunction in ME/CFS patients. PLoS One 18,510e0280942, doi:10.1371/journal.pone.0280942 (2023).

- 51130Ahamed, J. & Laurence, J. Long COVID endotheliopathy: hypothesized mechanisms512and potential therapeutic approaches. J Clin Invest 132, doi:10.1172/JCI161167513(2022).
- 51431Al-Yafeai, Z. et al. Endothelial FN (Fibronectin) Deposition by alpha5beta1 Integrins515Drives Atherogenic Inflammation. Arterioscler Thromb Vasc Biol 38, 2601-2614,516doi:10.1161/ATVBAHA.118.311705 (2018).
- 51732Cosio, F. G., Mahan, J. D. & Sedmak, D. D. Experimental glomerulonephritis induced518by antigen that binds to glomerular fibronectin. Am J Kidney Dis 15, 160-168,519doi:10.1016/s0272-6386(12)80514-2 (1990).
- Niddam, A. F. *et al.* Plasma fibronectin stabilizes Borrelia burgdorferi-endothelial
 interactions under vascular shear stress by a catch-bond mechanism. *Proceedings of the National Academy of Sciences of the United States of America* 114, E3490-E3498,
 doi:10.1073/pnas.1615007114 (2017).
- 52434Chen, H. Y., Lin, M. H., Chen, C. C. & Shu, J. C. The expression of fibronectin is525significantly suppressed in macrophages to exert a protective effect against526Staphylococcus aureus infection. BMC Microbiol 17, 92, doi:10.1186/s12866-017-5271003-9 (2017).
- 52835Brissette, C. A. *et al.* The borrelial fibronectin-binding protein RevA is an early antigen529of human Lyme disease. *Clin Vaccine Immunol* **17**, 274-280, doi:10.1128/CVI.00437-53009 (2010).
- 53136Herbert, K. E. *et al.* Fibronectin and immune complexes in rheumatic diseases. Ann532Rheum Dis 46, 734-740, doi:10.1136/ard.46.10.734 (1987).
- 53337Bing, D. H., Almeda, S., Isliker, H., Lahav, J. & Hynes, R. O. Fibronectin binds to the534C1q component of complement. Proceedings of the National Academy of Sciences of535the United States of America 79, 4198-4201, doi:10.1073/pnas.79.13.4198 (1982).
- 536
 38
 Sandig, H. et al. Fibronectin is a TH1-specific molecule in human subjects. The Journal

 537
 of allergy and clinical immunology
 124, 528-535, 535 e521-525,

 538
 doi:10.1016/j.jaci.2009.04.036 (2009).
- 53939Kelsh, R., You, R., Horzempa, C., Zheng, M. & McKeown-Longo, P. J. Regulation of the540innate immune response by fibronectin: synergism between the III-1 and EDA541domains. PLoS One 9, e102974, doi:10.1371/journal.pone.0102974 (2014).
- 542
 40
 Thurlow, P. J., Kenneally, D. A. & Connellan, J. M. The role of fibronectin in platelet

 543
 aggregation. Br J Haematol 75, 549-556, doi:10.1111/j.1365-2141.1990.tb07797.x

 544
 (1990).
- 54541Gondokaryono, S. P. *et al.* The extra domain A of fibronectin stimulates murine mast546cells via toll-like receptor 4. J Leukoc Biol 82, 657-665, doi:10.1189/jlb.1206730547(2007).
- 54842Dziarski, R. Modulation of polyclonal activation by plasma fibronectin and fibronectin549fragments. *Immunology* **61**, 111-116 (1987).
- 55043Gronwall, C., Vas, J. & Silverman, G. J. Protective Roles of Natural IgM Antibodies.551Front Immunol 3, 66, doi:10.3389/fimmu.2012.00066 (2012).
- 552
 44
 Klein, S. L. & Flanagan, K. L. Sex differences in immune responses. Nat Rev Immunol

 553
 16, 626-638, doi:10.1038/nri.2016.90 (2016).
- Panda, S., Zhang, J., Tan, N. S., Ho, B. & Ding, J. L. Natural IgG antibodies provide
 innate protection against ficolin-opsonized bacteria. *The EMBO Journal* 32, 29052919, doi:10.1038/emboj.2013.199 (2013).

- 46 Quach, T. D. *et al.* Distinctions among Circulating Antibody-Secreting Cell Populations,
 558 Including B-1 Cells, in Human Adult Peripheral Blood. *J Immunol* 196, 1060-1069,
 559 doi:10.4049/jimmunol.1501843 (2016).
- 56047Mina, M. J. et al. Measles virus infection diminishes preexisting antibodies that offer561protectionfromotherpathogens.Science366,599-606,562doi:10.1126/science.aay6485 (2019).
- 563 48 Smith, F. L. *et al.* B-1 plasma cells require non-cognate CD4 T cell help to generate a 564 unique repertoire of natural IgM. *J Exp Med* **220**, doi:10.1084/jem.20220195 (2023).
- 56549Elias, S. et al. CXCR4+ Treg cells control serum IgM levels and natural IgM566autoantibody production by B-1 cells in the bone marrow. J Exp Med 219,567doi:10.1084/jem.20220047 (2022).
- 56850Mandarano, A. H. *et al.* Myalgic encephalomyelitis/chronic fatigue syndrome patients569exhibit altered T cell metabolism and cytokine associations. J Clin Invest 130, 1491-5701505, doi:10.1172/JCI132185 (2020).
- 571

572 Acknowledgements:

573 The study was carried out using the clinical-scientific infrastructure of NAPKON (Nationales 574 Pandemie Kohorten Netz, German National Pandemic Cohort Network) of the Network 575 University Medicine (NUM), funded by the Federal Ministry of Education and Research 576 (BMBF).

577 We gratefully thank all NAPKON sites who contributed patient data and/or biosamples for 578 this analysis. We also thank the NAPKON Steering Committee: University Hospital Giessen 579 and Marburg, Giessen (Herold S), University of Wuerzburg, Wuerzburg (Heuschmann P), 580 Charité - Universitätsmedizin Berlin, Berlin (Heyder R), University Medicine Greifswald, 581 Greifswald (Hoffmann W), Hannover Unified Biobank, Hannover Medical School, Hannover 582 (Illig T), University Hospital Schleswig-Holstein, Kiel (Schreiber S), University Hospital 583 Cologne and University Hospital Frankfurt, Cologne and Frankfurt (Vehreschild JJ), Jena 584 University Hospital, Jena (von Lilienfeld-Toal M), Charité - Universitaetsmedizin Berlin, Berlin 585 (Witzenrath M).

586 We would like to thank the Core Unit for Confocal Microscopy and Flow Cytometry-based 587 Cell Sorting of the IZKF Würzburg for supporting the study. We thank Uta Behrends, 588 Technische Universität München (TUM) for kindly providing ME/CFS and healthy control 589 samples for this study. We thank Timo Ludwig for providing demographics from STAAB 590 database.

591

592 Funding:

593 We thank Amar Foundation, USA for a career development grant (BKP), ME Research UK 594 (BKP) and Bundesministerium für Bildung und Forschung (BMBF) (grant number 01EJ2204E) (BKP) for supporting this work. This research was also supported by the National Institutes 595 596 of Health (NIH/NIAID), USA, grant RO1AI084898-06 (MEA and MW) and The infectious 597 Diseases Society of America (IDSA) Foundation, USA, grant (MEA). The COVIDOM study is 598 part of the National Pandemic Cohort Network (NAPKON). NAPKON is funded by COVID-19-599 related grants from the Network University Medicine (NUM; NAPKON grant number: 600 01KX2021). Parts of the infrastructure of the Würzburg study site was funded by the federal 601 state of Bavaria. The STAAB Cohort study was supported by the German Ministry of Research and Education within the Comprehensive Heart Failure Centre Würzburg (BMBF 01EO1004 602 603 and 01EO1504). This study was, further, supported by the German Research Foundation

604 (DFG) through the Comprehensive Research Center 1525 'Cardio-immune interfaces'

605 (453989101, project C5) (CM and NB) and the Interdisciplinary Center for Clinical Research -

- 606 IZKF Würzburg (advanced clinician-scientist program; AdvCSP 3) (CM).
- 607

608 Author Contribution:

609 BKP conceived the idea, developed and supervised the project. ZL, CH, AG, AK carried out 610 majority of experiments; IMP carried out autophagosome work; SK carried out multivariate 611 and other statistical data analysis; AH, CN, VC, BA, TB, SC, JJV, OM, CS, KL, KT, JR, FE, LS, PUH, 612 SS, CM, FS, CS, NB, SK, GR contributed with patient recruitment, sample collection, patient 613 data management; MEA and MW contributed with important reagents and experiments; AS 614 and SL carried out mass spectrometry studies and related data analysis, RN supervised 615 mitochondrial experimental work, analyzed the data. BKP drafted the manuscript with help 616 from MEA. All other authors critically revised the manuscript. All authors approved the 617 submitted version.

618

619 **Competing Interests:**

- 620 The authors declare that they have no competing interests.
- 621

622 Materials availability:

623 Further information and requests for resources and reagents should be directed to Bhupesh

- 624 K Prusty (<u>bhupesh.prusty@uni-wuerzburg.de</u>).
- 625

626 Data availability:

The mass spectrometry proteomics data for the serum immunoglobulin proteome study have been deposited to the ProteomeXchange Consortium via the PRIDE partner repository with the dataset identifier PXD041945 and the same for HEK293 dUTPase co-IP proteome study with the dataset identifier PXD041942. All the experimental data are deposited to Mendley (doi: 10.17632/4xkft5g9r5.1).

632

633 Figure legends:

634

Fig. 1: Reactivation of EBV in ME/CFS and long COVID patients and the role of viral
 dUTPase protein in cellular manipulation.

- 637 a. Immunoblot based detection of IgG against herpesvirus dUTPase in human serum. Virus-
- 638 specific recombinant protein bands detected by IgG are indicated.
- 639 **b**. Likert chart showing percentage of positivity for antibodies against EBV, HSV-1 and HHV-6
- 640 dUTPase within healthy controls (HC), ME/CFS, Covid-19 PCR positive but without long

641 COVID (No LC), mild LC and severe LC patients. Kruskall Wallis (and its higher order

- 642 equivalent, ScheirerRayHare Test) rank sum test for antibody state. EBV, *P = 0.015; HSV-1,
- 643 *P = 0.068; HHV-6, **P = 0.002.
- 644 Mann-Whitney non-parametric test for EBV dUTPase HC vs ME/CFS, ***P = 0.0008; for HSV-
- 1 dUTPase HC vs severe LC, P = 0.051; for HSV-1 dUTPase No LC vs severe LC, *P = 0.013.
- 646 Different amounts IgG levels in patient serum was arbitrarily divided into 4 groups (0,
- 647 absent; 1, low; 2, moderate; 3, high).

c. Confocal images shows hyperpolarization of mitochondria in HEK293 cells under transient
 expression of HSV-1, HHV-6 and EBV dUTPases. Mock vector backbone was used as a
 control.

- 651 **d.** Average mitochondrial surface area from 5 biological replicates are plotted in the form of
- a scatter plot. n=5. Unpaired two-tailed non-parametric t-test. Mock vs EBV dUTPase, *P =

653 0.0414; Mock vs HHV-6 dUTPase, **P = 0.0077; Mock vs HSV-1 dUTPase, *P = 0.0479.

654 e. Immunoblot analysis shows increase in mitofusin1 (Mfn1) and decrease in LC3 β protein

levels in presence of herpesvirus dUTPases. GAPDH staining was used as a loading control.

656 Mean Mfn1 and LC3 β protein levels are presented as scatter plots. Data from 3 independent

medRxiv preprint doi: https://doi.org/10.1101/2023.06.23.23291827; this version posted June 29, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.

657 experiments. n=3. Unpaired two-tailed non-parametric t-test. For Mfn1, *P = 0.03 (Mock vs

658 HHV-6); *P = 0.01 (Mock vs HSV-1). For LC3 β , *P = 0.01 (Mock vs EBV); *P = 0.05 (Mock vs

659 HHV-6).

660 **f.** EBV dUTPase interferes with autophagosome assembly.

661 g. TMRE dyes were used to study mitochondrial membrane potential and OXPHOS in

662 HEK293 cells. Cells were transiently transfected with herpesvirus dUTPases or a mock vector

663 for 48 h. Trypsinized cells were stained with TMRE dye and were used for flow cytometry.

664 Oligomycin was used to inhibit ATP synthase. Data from 3 independent experiments. n=3.

665 MFI, mean fluorescence intensity.

666 **h.** Normalized log2 ratio of LFQ (label-free quantitation) intensities of proteins. Fold change

of proteins in HSV-1 vs Mock was plotted against the same in EBV vs Mock to highlight proteins that were common and were enriched in both sample sets. Circles indicate identified cellular proteins; circle size correlates with the number of razor and unique peptides used for quantification. Significantly enriched proteins that are potential interaction partners of EBV and HSV-1 dUTPases are displayed in red.

672 **i.** Immunoblot analysis to validate potential herpesvirus dUTPase interacting partners 673 identified from co-IP. GAPDH staining was used as a negative control.

674

Fig. 2: Autoimmunity, mitochondrial alterations and circulating Fibronectin levels in
 ME/CFS.

a. Confocal images show mitochondrial architecture in primary HUVEC cells exposed to 1µg
of purified IgG from patient sera. Two different representative images for each condition is
shown.

medRxiv preprint doi: https://doi.org/10.1101/2023.06.23.23291827; this version posted June 29, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.

b. Average mitochondrial surface area in primary HUVEC cells exposed to 1μg of purified IgG
from patient sera is quantified and compared between healthy controls, mild/moderate,
severe ME/CFS. Data from three independent experiments from each serum sample is
shown as a violin plot. n=3. Two-tailed non-parametric test. Healthy control vs
mild/moderate ME/CFS, *P = 0.0329. Healthy control vs severe ME/CFS, **P = 0.0046.
Mild/moderate vs severe ME/CFS, ****P < 0.0001.

c. Immunoblot analysis shows decrease in mitofusin1 (Mfn1) and PLD6 protein levels in
HUVEC cells exposed to 1μg of purified IgG from patient sera for 12 h. Actin staining was
used as a loading control. Fold change values were derived from densitometric analysis of
bands after normalization with the same for actin. n=2. HD, healthy donors; CFS, severe CFS
patients.

d. Heat map of log2 fold LFQ intensities of proteins detected within purified immune
 complexes from patient sera. Three proteins that showed differential protein levels between
 healthy controls and ME/CFS patients are shown.

694 e. Multivariate analysis of clusters based on distance metrics derived from IgM antibody
695 levels for a panel of autoantigens. Log-transformed scaled data showing relative differences
696 between different variable in both healthy controls and patients.

697 **f**. The Variables Factor map for the Principal Components (for Patients and Healthy Controls

698 combined data) shows the projection of the top 10 Autoantigen variables projected onto the

- 699 plane spanned by the first two Principal Components.
- 700 g. Serum fibronectin (FN1) levels in patient sera. Log2 values of FN1 are presented as a violin
- plot. Two-tailed parametric t-test. Healthy control (HC) vs ME/CFS, **P = 0.005.

702 **h.** Kernel density plot showing the bivariate serum FN1 distributions among healthy controls

and ME/CFS patients. FN1 concentrations on both X- and Y-axis are presented as µg/ml.

medRxiv preprint doi: https://doi.org/10.1101/2023.06.23.23291827; this version posted June 29, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.

i. Circulating fibronectin (FN1) levels correlates with ME/CFS severity associated Bell score.

- Log2 fold FN1 vales are presented as a violin plot. Two-tailed parametric t-test. HC vs Bell 0-
- 706 20, ****P < 0.0001. Bell 0-20 vs Bell 30-50, **P = 0.0032.
- **j.** AUROC analysis for circulating FN1 levels in healthy controls (HC) vs severe ME/CFS
- 708 patients.
- 709 **k.** Serum fibronectin (FN1) levels in different patient groups post SARS-CoV-2 infection. Log2
- values of FN1 are presented as a violin plot. Two-tailed parametric t-test. Healthy control
- 711 (HC) vs mild LC, **P = 0.0032. HC vs severe LC, *P = 0.0488. ns, not significant.
- 712

Fig. 3: IgM and IgG levels against Fibronectin in ME/CFS and long COVID.

- **a.** IgM levels against fibronectin (IgM-FN1) in patient sera. Log2 fold IgM-FN1 amounts are
- presented as a violin plot. Two-tailed parametric t-test. Healthy control (HC) vs SARS CoV-2
- positive but without long COVID (No LC), HC vs mild LC, HC vs severe LC, ****P < 0.00001.
- 717 No LC vs severe LC, *P = 0.0376. ns, not significant.
- **b.** IgG levels against fibronectin (IgM-FN1) in patient sera. Log2 fold IgG-FN1 amounts are
- presented as a violin plot. Two-tailed parametric t-test. Healthy control (HC) vs SARS CoV-2
- positive but without long COVID (No LC), HC vs mild LC, HC vs severe LC, ****P < 0.00001.
- ns, not significant.
- 722 **c.** IgM-fibronectin (FN1) levels correlates with ME/CFS severity associated Bell scores. Log2
- fold IgM-FN1 vales are presented as a violin plot. Two-tailed parametric t-test. HC vs Bell 0-

724 20, **P = 0.0046. Bell 0-20 vs Bell 30-50, ***P = 0.0002.

d. IgG-fibronectin (FN1) levels does not correlate with ME/CFS severity associated Bell
scores. Log2 fold IgG-FN1 vales are presented as a violin plot. Two-tailed parametric t-test.
Ns, not significant.

medRxiv preprint doi: https://doi.org/10.1101/2023.06.23.23291827; this version posted June 29, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.

728	e. IgM levels against phosphorylcholine (IgM-PC) in patient sera. Log2 fold IgM-PC amounts
729	are presented as a violin plot. Two-tailed parametric t-test. Healthy control (HC) vs mild LC,
730	***P = 0.0002. HC vs severe LC, ***P = 0.0006. No LC vs severe LC, *P = 0.0216. No LC vs
731	mild LC, *P = 0.0111. ns, not significant.
732	f. IgM levels against malondialdehyde (IgM-MDA) in patient sera. Log2 fold IgM-MDA
733	amounts are presented as a violin plot. Two-tailed parametric t-test. Healthy control (HC) vs
734	mild LC, *P = 0.0175. HC vs severe LC, **P = 0.0068. No LC vs severe LC, *P = 0.0209. No LC
735	vs mild LC, *P = 0.0525. ns, not significant.
736	g. AUROC analysis for IgM-FN1 levels in healthy controls (HC) vs SARS CoV-2 positive but
737	without long COVID (No LC) patients.
738	h. AUROC analysis for IgM-FN1 levels in healthy controls (HC) vs mild LC patients.
739	i. AUROC analysis for IgM-FN1 levels in healthy controls (HC) vs severe LC patients.
740	
741	Fig. 4: IgM-FN1 and circulating fibronectin as a biomarker in ME/CFS and long COVID.
742	a. Multi-variate AUROC analysis for circulating FN1 and IgM against fibronectin (IgM-FN1) in
743	healthy controls (HC) vs severe ME/CFS patients. Multiple logistic regression. $****P$ <
744	0.0001.
745	b. Multi-variate AUROC analysis for circulating FN1 and IgM against fibronectin (IgM-FN1) in
746	healthy controls (HC) vs severe LC patients. Multiple logistic regression. ****P < 0.0001.
747	c. Multiple variable bubble plot with circulating FN1 levels plotted against IgM-FN1 for
748	healthy controls (HC) and severe ME/CFS patients.
749	${\bf d.}$ Multiple variable bubble plot with circulating FN1 levels plotted against IgM-FN1 for
750	healthy controls (HC) and total long COVID patients (mild LC + severe LC).

- 751 e. Multiple variable bubble plot with circulating FN1 levels plotted against IgM-FN1 for
- 752 ME/CFS and total long COVID patients (mild LC + severe LC).
- 753 f. Multiple variable bubble plot with circulating FN1 levels plotted against IgM-FN1 for
- severe ME/CFS (with Bell 0-20) and severe long COVID patients.

- **Supplementary Table 1:** Patient demographics.
- **Supplementary Table 2:** List of antigens used in the microarray study.
- **Supplementary Table 3:** List of plasmids used in the study.
- **Supplementary Table 4:** List of antibodies used in the study.
- **Supplementary Table 5:** Inter- and Intra-assay variations in IgM and IgG ELISA.

767 Online-only Methods

768 Patient recruitment and serum collection

769 Long COVID patient cohort: COVIDOM is a prospective, population-based cohort study to 770 investigate the long-term health sequelae of SARS-CoV-2 infection. Details have been reported elsewhere^{1,2}. COVIDOM was approved by the local ethics committees of the 771 772 university hospitals of Kiel (No. D 537/20), and Würzburg (No. 236/20 z) and was registered 773 at clinicaltrials.gov (NCT04679584) and at the German Registry for Clinical Studies (DRKS, 774 DRKS00023742). COVIDOM participants of the Würzburg sub-cohort were recruited in the 775 catchment area of Würzburg and identified through local public health authorities so as to 776 address an unbiased subpopulation regarding age, sex, hospitalization, and media literacy. 777 Main inclusion criteria were (i) a polymerase chain reaction (PCR) confirmed SARS-CoV-2 778 infection and (ii) a period of at least 6 months between the infection and the visit to the 779 COVIDOM study site. During the on-site examination participants underwent detailed 780 cardio-pulmonary phenotyping and blood was drawn. Serum was stored at Interdisciplinary 781 Bank of Biomaterials and Data of the University Hospital of Würzburg (ibdw). Long COVID severity was determined on the basis of a previously described scoring system¹. 782

783 **ME/CFS patient cohort:** ME/CFS patients, and gender- and age matched healthy controls 784 were diagnosed at the outpatient clinic at the Charité Universitätsmedizin, Berlin and 785 Technische Universität München (TUM) between 2020 and 2023. Diagnosis of ME/CFS in all 786 patients was based on the 2003 Canadian Consensus Criteria and exclusion of other medical 787 or neurological diseases that may cause fatigue by a comprehensive clinical and laboratory 788 evaluation. The study was approved by the Ethics Committee of Charité Universitätsmedizin 789 Berlin (EA2/067/20; EA2 066 22; EA4 174 22) and TUM (112/14 (healthy controls) and 790 529/18 (pediatric ME/CFS), 485/18 adult ME/CFS) in accordance with the 1964 Declaration 791 of Helsinki and its later amendments. Some of the patient samples were also collected at 792 University of California San Diego with signed informed consent under UCSD IRB Project 793 #140072, "The UCSD Metabolomics Study". All patients gave informed consent. Whole 794 blood samples from each subject were allowed to clot at room temperature and then 795 centrifuged at 2000 x g for 10 min. The serum was stored in aliquots at -80°C.

Healthy controls: For long COVID studies, additional healthy controls were used from the
 population-based Characteristics and Course of Heart Failure Stages A-B and Determinants
 of Progression (STAAB) Cohort that recruited individuals without self-reported HF from the

799 general population of Würzburg, Germany, aged 30-79 years and stratified for age and sex. The detailed study design and methodology have been published³. All study related 800 procedures were subjected to a rigid and regular quality control process⁴. The STAAB cohort 801 802 study protocol and procedures comply with the Declaration of Helsinki and received positive 803 votes from the Ethics Committee of the Medical Faculty as well as from the data protection 804 officer of the University of Würzburg (vote #98/13). All participants provided written 805 informed consent prior to any study examination. During the baseline visit, a fasting blood 806 sample was taken and serum was stored in the Interdisciplinary Bank of Biomaterials and 807 Data of the University Hospital of Würzburg (ibdw). For the current project, we identified a 808 random cohort of samples of STAAB participants, between the age 40 and 79 years. Overall 809 characteristics of the patient cohort is summarized in Supplementary Table 1.

For all the above-mentioned patient and healthy control study groups, there were no statistically significant differences in age between male and female subjects except for healthy controls (p = 0.018).

813

814 Cell culture

815 U2-OS (HTB-96), HEK293 (CRL-1573) cells were purchased from ATCC and HUVEC-TERT2 cells 816 (CHT-006-0008) were purchased from Evercyte, Austria. U2-OS and HEK293 cells were grown 817 in McCoy's 5A and DMEM media respectively supplemented with 10% (v/v) FBS and 200 818 units/ml penicillin-streptomycin. HUVEC-TERT2 cells were grown in EBM basal medium 819 (Lonza, Cat#CC-3121) supplemented with Components of EGM SingleQuot Kit (Lonza, Cat# 820 CC-4133: BBE, hEGF, hydrocortisone, ascorbic acid), 10% FBS and 20 µg/ml G418. All cell lines were cultured at 37 $^{\circ}$ C with 5% CO₂. Cells carrying stable GFP expression within 821 822 mitochondria were developed as mentioned before⁵. Cells stably expressing the 823 mitochondrial targeted GFP were created by cloning the mitochondrial targeted GFP into 824 pLVTHM vector backbone (Supplementary Table 3) and transducing target cells with the lentivirus as mentioned before⁵. All the cell lines were frequently tested for Mycoplasma 825 826 contamination and were authenticated by sequencing, wherever necessary.

827

828 dUTPase constructs, recombinant protein purification

829 Constructs used in this study are detailed in Supplementary Table 3. Briefly, HSV-1 dUTPase 830 (UL50), HHV-6A dUTPase (U45) and EBV dUTPase (BLLF3) were cloned from bacterial

artificial chromosome (BAC) carrying the full-length viral genome. pFN22A vector backbone was used to clone the viral dUTPases carrying N-terminal Halo-tag. All the constructs were sequenced to confirm absence of mutations within the dUTPase open reading frames. A mock dUTPase was created to be used as experimental control by digesting the pFN22Ahalo-HHV-6 dUTPase construct with Xbal restriction enzyme which removed majority of viral dUTPase except for 186 bp N-terminal sequences. Digested construct was religated, sequence verified and used as mock control.

838

839 For dUTPase recombinant protein preparation, bacterial Strain BL21 (DE3)plyS: F-, ompT, 840 hsdSB (rB-mB-) gal, dcm with chloramphenicol resistance was used. pTrcHIS vector (Thermo 841 Fischer Scientific) was selected using Ampicillin resistance. Depending on the particular 842 dUTPases constructs, bacterial pellets were obtained from 6 to 54 liters of Luria-Broth (LB) 843 culture. An overnight culture was prepared by inoculation of 100-200 μ l of the bacterial 844 strain into 200 ml of LB medium containing ampicillin (100 μ g/ml) and chloramphenicol (5 845 μ g/ml). with shaking at 37 °C. Next day, a fresh inoculation was prepared by mixing 1 liter of 846 LB medium containing ampicillin and chloramphenicol with 20-25 ml of the overnight 847 culture and was incubated at 37 °C for 2 h with shaking. IPTG was added to the inoculated 848 medium at a concentration of 24 μ g/ml with a further incubation of 2 h with shaking at 37 849 $^{\circ}$ C. Bacterial cells were centrifuge at 5000 rpm for 5 min and pellets were frozen down at -20 850 °C till protein extraction. On the day of protein preparation, thawed cell pellets were mixed 851 in column equilibration buffer (50 mM sodium phosphate, 300 mM NaCl and 10 mM 852 imidazole, pH 7.4), sonicated for 4 min (1 min burst; 1 min rest) on ice, centrifuged at 10,000 853 rpm for 30 min and the the supernatant was stored at 4 °C till the next day. HisPurTM Cobalt 854 3 ml spin columns were used under native conditions for protein purification. dUTPase 855 proteins were eluted with elution buffer (50 mM sodium phosphate, 300 mM NaCl and 150 856 mM imidazole, pH7.4).

857

858 Average mitochondrial surface area and mitochondrial number analysis

Software and modified algorithm for mitochondrial size and number measurement were previously described by us in detail^{5,6}. All image-processing and analysis steps were performed using Fiji⁷.

862

863 Immunofluorescence Microscopy

A detailed protocol for standard immunofluorescence microscopy is previously described⁸. All the antibodies used in the immunofluorescence studies are described in Supplementary Table 4. Halo-tagged dUTPase expression and cellular localization was visualized using Halotag TMRDirect ligand (Promega, Cat. G2991).

868

869 Immunoblotting

870 Immunoblotting was carried out as described before^{8,9} using antibodies mentioned in 871 Supplementary Table 4. Equal protein loading was confirmed by using antibodies against β -872 actin or GAPDH. All the primary antibodies were used at a dilution of 1:1000 and the HRP-873 conjugated secondary antibodies were used at a dilution of 1:10,000.

a. Western blot for detecting fibronectin in serum: Serum samples were diluted 1:1 by
2X Laemmli buffer (100 mM Tris pH 6.8, 4% SDS, 0.2% bromophenol blue, 20% glycerol and
200 mM β-mercaptoethanol) and then further diluted 1:100 by 1X Laemmli buffer (50 mM
Tris pH 6.8, 2% SDS, 0.1% bromophenol blue, 10% glycerol and 100 mM β-mercaptoethanol).
10 µl diluted serum samples were loaded onto 4-10% gradient SDS-PAGE gels. 1 µg of human
plasma fibronectin (Sigma-Aldrich, F2006) and 0.1 µg fibronectin fragment 2 (Sino Biological,
10314-H08H) were loaded as control onto the SDS-PAGE gels.

b. Western blot for detecting natural IgM and IgG: 1 μg of human plasma fibronectin
(Sigma-Aldrich, F2006) and 0.1 μg fibronectin fragment 2 (FN1.2) (Sino Biological, 10314H08H) were loaded onto SDS-PAGE gels. Each blot was incubated with 50 ul of human serum
in 5 ml of 3% BSA for overnight at 4 °C. HRP-conjugated anti-human IgG or IgM was used
(1:10000 dilution) for detecting the fibronectin bound IgG or IgM.

c. Western blot for detecting IgG against herpesvirus dUTPase: 5 μg of recombinant
EBV, HSV-1 and HHV-6 dUTPase proteins were loaded onto 10% SDS-PAGE gels. After gel
running and transfer onto a nitrocellulose membrane, each membrane was incubated with
50 ul of human serum in 5 ml of 3% BSA for overnight at 4 °C. HRP-conjugated anti-human
IgG was used (1:10000 dilution) for detecting the IgG against individual herpesvirus
dUTPases. Intensities of appropriate bands were quantified using densitometric analysis. An
arbitrary grading system (0, 1, 2 and 3) was used to evaluate amounts of IgG response

against respective herpesvirus dUTPases. 0, absent (no IgG response detected); 1, low; 2,
moderate; 3, high. Specificity and cross-reactivity of individual herpesvirus IgG against each
other was checked.

896

897 Analysis of mitochondrial membrane potential by TMRE (Tetramethylrhodamine-898 ethylester-perchlorate)

899 For the analysis of mitochondrial membrane potential HEK293 cells were seeded in 6 well 900 plates. Cells were transfected with plasmids encoding Halo-tagged herpesvirus dUTPase 901 (Supplementary Table 3). After 48 hours cells were trypsinized, washed and counted. For TMRE staining (Sigma-Aldrich, 87917) 2 X 10⁶ cells were washed with PBS and resuspended 902 903 in a 50 nM TMRE solution in PBS and 137 mM KCl and stained for 10 min at room 904 temperature. Cells were measured by flow cytometer (Attune Flow Cytometers) recording 905 first base level of TMRE fluorescence. Then, half of the cells were treated with 1.5 μ M of 906 Oligomycin (Sigma Aldrich, #04876 in DMSO). Fluorescence was measured at different 907 timepoints of incubation. At the end, 5 μ M FCCP (Carbonyl cyanide-p-trifluoromethoxy-908 phenylhydrazone, Sigma Aldrich, #C2920) was added to induce mitochondrial depolarization 909 and the changes in fluorescence levels because of loss of membrane potential was 910 measured.

911

912 Immunoglobulin purification

913 150 µl Protein G Sepharose 4 Fast Flow (#17061801,cytiva) was loaded onto Poly-Prep
914 Chromatography Columns (#731-1550, BIO-RAD). After washing the beads with PBS, 500 µl
915 serum sample was loaded and passed through the column 3 times, which was followed by 3
916 time washing by PBS. Protein G bounded serum IgG was eluted by Glycine pH 2.7 and then
917 neutralised with 1M Tris-HCl pH 8.0. IgG elute was dialyzed against PBS in Slide-A-Lyzer MINI
918 Dialysis Devices (#88404, Thermo Fisher Scientific). IgG concentration was measured by
919 Easy-Titer Human IgG (H+L) Assay Kit (#23310, Thermo Fisher Scientific).

920

921 **Co-immunoprecipitation of His-tagged viral dUTPases**

922 Halo-tagged herpesvirus dUTPase immunoprecipitation (IP) was carried out using standard

923 IP protocol⁵ using ysis buffer (50 mM Hepes, pH 7,5; 150 mM NaCl; 0.5% NP-40; 1 mM NaF;

924 10% Glycerol, 2.5 mM MgCl₂; protease inhibitor cocktail (Roche), 0.5 mM DTT) and wash
925 buffer (50 mM Hepes, pH 7,5; 150 mM NaCl; 1 mM NaF; 10% Glycerol, 2.5 mM MgCl₂;
926 protease inhibitor cocktail (Roche), 0.5 mM DTT).

927

928 IgG exposure in cell culture

U2-OS or HUVEV-TERT2 cells carrying soluble mitoGFP were seeded on 6-well plates and
 cultured overnight. Cell culture medium containing 1 μg/ml serum IgG was added to each
 well, allowing cells to be exposed to serum derived IgG. Cells were collected after 24 h for
 western blot or immunofluorescence experiments.

933

934 Fibronectin ELISA

935 Human fibronectin ELISA was performed with Fibronectin Human ELISA Kit (#BMS2028,

936 Thermo Fisher Scientific) by the manufacturer's protocol.

937

938 IgM-FN1 and IgG-FN1 ELISA

939 96 well microplates (Sigma-Aldrich, CLS9018) were coated with 100 ng fibronectin antibody 940 (Santa Cruz, sc-18825) in carbonate coating buffer (Thermo Fisher Scientific, CB01100) 941 overnight at 4°C. For IgG and IgM standard wells, 100 μ l 25.60 ~ 0 pg/ μ l series dilutions of 942 native human IgM protein (Abcam, ab90348) or human IgG isotype control (Thermo Fisher 943 Scientific, 31154) was coated onto the plates in carbonate coating buffer (Thermo Fisher 944 Scientific, CB01100) overnight at 4°C. Plates were then washed 3 times for 5 min by 200 μ l 945 1X wash buffer on a plate shaker, which was prepared by diluting 20X TBST (Thermo Fisher 946 Scientific, 28360) in distilled water. 2% BSA (Bovine Serum Albumin) (Sigma-Aldrich, A2153) 947 was dissolved in 1X washing buffer. $300 \ \mu$ l 2% BSA were used to block the plates for 1h at RT 948 and the plates were washed 1 time afterwards. Serum samples from patients and healthy 949 control were diluted 1:100 by 2% BSA. Plates were then incubated with 100 μ l diluted serum 950 samples in each well for 1 h at RT on a shaker. Plates were then washed 6 times for 5 min by 951 200 μ l 1x washing buffer on a shaker. Goat anti-human IgM-HRP (Thermo Fisher Scientific, 952 31415) and rabbit anti-human IgG-HRP (Sigma-Aldrich, A8792) were used as secondary 953 antibodies for signal detection. Secondary antibodies were diluted 1:10000 in 2% BSA. Plates 954 were incubated with 100 μ l of diluted secondary antibody for 1h at RT and then washed 6 955 times for 5 min by 200 μ l 1X washing buffer on a plate shaker. HRP signals were developed

by incubating the plates with 100 µl TMB substrate solution (Thermo Fisher Scientific,
34029) for 15-30 minutes at RT until desired color was visible and then stopping the reaction
by adding 100 µl stop solution (Thermo Fisher Scientific, SS04). Plates were immediately
read by an optical plate reader (Avantor, SpectraMax PLUS384) at 450 nm. The
concentration of the samples was calculated by using the standard curves as references.
Duplicates were applied for all unknown samples and standard samples.

962

963 Principles of sandwich ELISA: Fibronectin antibody (Santa Cruz, sc-18825) was raised against 964 the cell binding domain, which is located within the FN1.2 domain. However, natural IgM 965 against fibronectin only showed binding activity with plasma fibronectin instead of 966 recombinant FN1.2, suggesting that natural IgM against fibronectin and fibronectin antibody 967 (Santa Cruz, sc-18825) have different binding domain. Based on this, we developed our 968 sandwich ELISA for IgM and IgG.

969

970 Inter- and Intra-assay validation for IqM-FN1 and IqG-FN1: For inter- and intra-assay 971 accuracy testing, optical density (O.D.) values at 450 nm for standard concentration curves 972 between the range of 0.8 ng/ml to 25.6 ng/ml human native IgM and human IgG controls 973 were generated (Supplementary Table 5a and 5b respectively). Two independent 974 experiments on three different days (Six independent standard curves in total), for both IgM 975 and IgG, were developed and carried out. Intra-assay precision was assessed over these six 976 independent standard concentration curves. Each standard concentration was performed in 977 duplicates. The results showed overall intra-assay coefficients of variation (CV) of 3.45% 978 (range between 0.00% to 14.93%) for IgM and 2.67% (range between 0.00% to 8.62%) for 979 IgG. Inter-assay reproducibility was determined by the overall CV of all mean O.D. values 980 from six independent experiments. The results showed CV of 3.22% (range between 0.02% 981 to 11.47%) for IgM and 3.23% (range between 0.03% to 11.48%) for IgG.

982

983 Mass spectrometry

A fraction of serum IgG bounded protein G beads from IgG purification was eluted by
NuPAGE LDS Sample Buffer (4X) (#NP0007, Thermo Fisher Scientific). The elutes were sent
for mass spectrometry.

987

988 Single-pot, solid-phase-enhanced sample preparation (SP3)

Samples were processed using an adapted SP3 protocol¹⁰. Briefly, 200 μ l reconstitution 989 990 solution was added to each sample prepared in 50 µl NuPAGE LDS sample buffer (Life 991 Technologies). Reduction was performed using 5 mM DTT with subsequent alkylation with 992 20 mM iodoacetamide. 10mM additional DTT was used for quenching. Equal volumes of two 993 types of Sera-Mag Speed Beads (Cytiva, #45152101010250 and #65152105050250) were 994 combined, washed with water and $10\mathbb{I}\mu$ L of the bead mix were added to each sample. 260 995 µl 100% ethanol was added and samples were incubated for 5 min at 24 °C, 1000 rpm. Beads 996 were captured on a magnetic rack for 22min, and the supernatant was removed. Beads were 997 washed twice with 200 µl 80% ethanol (Chromasolv, Sigma) and then once with 1000 µl 80% 998 ethanol. Digestion was performed on beads with 0.25 µg Trypsin (Gold, Mass Spectrometry 999 Grade, Promega) and 0.25 µg Lys-C (Wako) in 100 µl 100 mM ammonium bicarbonate at 37 °C overnight. Peptides were desalted using C-18 Stage Tips¹¹. Each Stage Tip was prepared 1000 1001 with three discs of C-18 Empore SPE Discs (3 M) in a 200 μ l pipet tip. Peptides were eluted 1002 with 60 % acetonitrile in 0.1 % formic acid, dried in a vacuum concentrator (Eppendorf), and 1003 stored at -20 °C. Peptides were dissolved in 2 % acetonitrile / 0.1 % formic acid prior to 1004 nanoLC-MS/MS analysis.

1005

1006 NanoLC-MS/MS analysis

1007 NanoLC-MS/MS analyses were performed on an Orbitrap Fusion (Thermo Scientific) 1008 equipped with a PicoView Ion Source (New Objective) and coupled to an EASY-nLC 1000 1009 (Thermo Scientific). Peptides were loaded on a trapping column (2 cm x 150 μ m ID, PepSep) 1010 and separated on a capillary column (30 cm x 150 μ m ID, PepSep) both packed with 1.9 μ m 1011 C18 ReproSil and separated with a 120-minute linear gradient from 3% to 30% acetonitrile 1012 and 0.1% formic acid and a flow rate of 500 nl/min. Both MS and MS/MS scans were 1013 acquired in the Orbitrap analyzer with a resolution of 60,000 for MS scans and 30,000 for MS/MS scans. HCD fragmentation with 35 % normalized collision energy was applied. A Top 1014 1015 Speed data-dependent MS/MS method with a fixed cycle time of 3 s was used. Dynamic 1016 exclusion was applied with a repeat count of 1 and an exclusion duration of 90 s; singly charged precursors were excluded from selection. Minimum signal threshold for precursor 1017 selection was set to 50,000. Predictive AGC was used with AGC a target value of $4x10^5$ for 1018 MS scans and 5×10^4 for MS/MS scans. EASY-IC was used for internal calibration. 1019

1020

1021 **MS data analysis**

Raw MS data files were analyzed with MaxQuant version 1.6.2.2¹². Database search was 1022 1023 performed with Andromeda, which is integrated in the utilized version of MaxQuant. The 1024 search was performed against the UniProt Human Reference Proteome database (June 1025 2022, UP000005640, 79684 entries), the UniProt HHV-6 Reference Proteome database 1026 (October 2018, UP000009295, 107 entries) and the UniProt Epstein-Barr virus database 1027 (September 2022, UP000272970, 82 entries). For dUTPase co-IP experiment, a small 1028 database containing the sequence of the Halo-Tag (UniProt DHAA RHORH) and the 1029 dUTPases of interest (UniProt LON6A5, P30007, P03195) was used. Additionally, a database 1030 containing common contaminants was used. The search was performed with tryptic 1031 cleavage specificity with 3 allowed miscleavages. Protein identification was under control of 1032 the false-discovery rate (FDR; <1% FDR on protein and peptide spectrum match (PSM) level). 1033 In addition to MaxQuant default settings, the search was performed against following 1034 variable modifications: Protein N-terminal acetylation, Gln to pyro-Glu formation (N-term. 1035 GIn) and oxidation (Met). Carbamidomethyl (Cys) was set as fixed modification. LFQ intensities were used for protein guantitation¹³. 1036

1037

1038 For Halo-tag co-IP data analysis, proteins with less than two razor/unique peptides were 1039 removed. Missing LFQ intensities were imputed with values close to the baseline. Data 1040 imputation was performed with values from a standard normal distribution with a mean of 1041 the 5% quantile of the combined log10-transformed LFQ intensities and a standard deviation 1042 of 0.1. For the identification of significantly enriched proteins, boxplot outliers were 1043 identified in intensity bins of at least 300 proteins. Log2 transformed protein ratios of 1044 sample versus control with values outside a 1.5x (significance 1) or 3x (significance 2) 1045 interquartile range (IQR), respectively, were considered as significantly enriched.

1046

1047 Antigen Microarray experimental set up

1048 Microarray studies for IgM against autoantigens were carried out in collaboration with 1049 Creative Biolabs, USA. Frozen serum samples without prior freeze-thaw cycle were used for 1050 the assay. Each serum was digested with DNase I for 30 min at room temperature on a 1051 shaker. For the control, no serum sample was added. Slides carrying antigens against 120

1052 autoantigens (for details of the antigens, please see Supplementary Table 2) were blocked in 1053 100 ml blocking buffer at room temp for 30 min on a shaker. Afterwards slides were washed 1054 twice with PBST each for 5 min. 90 ml PBST was added into each serum sample or control 1055 mix. Diluted samples were added into each well of the slide (100 ml /each) and were 1056 incubate at room temp for 1 hour on a shaker. Slides were washed with PBST 100 ml/well for 1057 5 min on the shaker. Subsequently slides were washed with blocking buffer 100 ml/each well 1058 for 5 min on a shaker and the with PBST 100 ml/each well, 5 min on a shaker. Anti-human 1059 IgM secondary antibody were diluted to 1:1000 in PBST and 100 ml secondary antibody was 1060 added to each well. Slides were incubated at room temp for 1 hour on the shaker, washed 1061 three times with PBST 100 ml/each well, 5 min on the shaker. Slides were then washed twice 1062 each, first with 45 ml PBS in 50 ml tube for 5 min on the shaker and then with 45 ml 1063 nuclease-free water in 50 ml tube for 5 min on the shaker. GenePix 4000B microarray 1064 systems was used to scan the slide. 532 nm channel was used to scan Cy3 fluorescence, and 635 nm channel was used to scan Alexa Fluor-647 fluorescence. 1065

1066

1067 Microarray data analysis

1068 Each chip had serially diluted anti-IgM and IgM as positive control to monitor the 1069 experimental process, and PBS was used as a negative control. For the obtained chip image, 1070 LuxScan 3.0 software was used to read the original data. Statistical tests were then carried 1071 out on the chip background, the signal intensity of the positive and negative control sites. 1072 The results showed that the Ig control signal value was higher, and the uniformity was good 1073 in different samples. In addition, the value of PBS anti-Ig control and background signal value 1074 were all low, which met the quality control requirements. The chip of the test sample was 1075 scanned with LuxScan 10K-B scanner. Autoantigen microarray chip/ Pathogen-associated 1076 antigen microarray chip had 256 points in total. After removal of the 8 anti-IgM and 8 Ig 1077 control points, 240 data points were finally obtained. Each protein on the chip was present 1078 as two technical repetitions, representing 120 autoantigens. The chip is read by LuxScan 3.0 1079 software to obtain the original data, including foreground signal (F Median), background 1080 signal (B Median) and so on. Foreground Median, Background Median columns were 1081 extracted from the .LSR file. Fluorescence intensity value of each site was calculated by the formula: Net Fluorescence Intensity (NFI) Value = (Foreground Median - Background 1082 1083 Median); SNR = (Foreground Median - Background Median) / SD(Background). SNR was used

1084 to filter unreasonable data. The net fluorescence value was set as SNR <0.05 and SNR to 1085 0.001. The net fluorescence value was calculated after subtracting the blank control PBS 1086 NFI_{No PBS}. The NFI and SNR of the following unreasonable situations was set to 0.001. 1087 NFI < 20 and SNR > 5; SNR < 0.05 and NFI > 20; NFI < 0.05. RLM Normalization was used to 1088 normalize the NFI and calculate the effect values of different blocks and slides. For the 1089 microarray data clustering and multivariate analysis, first log transformation was carried out 1090 and then 'pheatmap' was used using R package with Ward.D2 clustering to make the cluster 1091 analysis.

1092

1093 Machine learning and Multivariate analysis of autoantigen IgM microarray data

1094 Multivariate analysis of patient clusters based on distance metrics derived from IgM 1095 antibody levels against for a panel of autoantigens. Columns with zero variation (constant 1096 values) were removed. Log-transformed scaled data showing relative differences between 1097 patients was used because the data in its raw form had different orders of magnitude, 1098 making analysis and comparison difficult. The analysis was performed using the R package 1099 "pheatmap" using Ward.D2 clustering method and Euclidean distances.

1100

A RandomForest classifier using the R package randomForest was fit predicting ME/CFS as an outcome was performed on two types of data - raw data and log scaled data. The purpose of this fit was a rapid screen for variables for further analysis. The Variable limportance Plot for the fits were plotted. The top 10 candidates from the Log Variable limportance Plots were selected for Principal Component Analysis (PCA), a statistical methodology for dimension reduction. PCA was was performed using the R package stats (prcomp) and FactoMineR.

1108

1109 Statistical testing of herpesvirus dUTPase antibody

As a part of the Likert Analysis, the following steps were performed: Counts and percentage of totals were generated in R using dplyr package. The above results were grouped into relevant sets (EBV, HSV-1, HHV-6, Healthy, ME/CFS, Covid-19 PCR positive but no long COVID (No LC), Mild LC, Severe LC). Likert charts were generated from the above groupings.

1114

1115 Non-parametric analysis was performed because the groups were of different sizes. The R 1116 package "rcompanion" was used because it has the higher order non-parametric 1117 ScheirerRayHare Test. Kruskall Wallis and its associated higher order test ScheirerRayHare 1118 Test were performed because two factors (Antibody State, i.e., 0, 1, 2, 3 and virus state, i.e., 1119 EBV, HSV-1, HHV-6) are changing simultaneously and it would be useful to know which 1120 factor was statistically significant. For several tests, it appeared that Antibody State was 1121 significant.

1122

1123 Other statistics

1124 Kernel density plot showing the bivariate serum FN1 distributions among healthy controls 1125 and ME/CFS patients was performed using the Python package package Seaborn 1126 (Seaborn.kdeplot) . All other statistical calculations were performed using GraphPad Prism 1127 9.0. Error bars displayed on graphs represent the means \pm SD of three or more independent 1128 replicates of an experiment. Statistical significance was calculated separately for each 1129 experiment and are described within individual figure legends. For image analysis, three or 1130 more biological replicates per sample-condition were used to generate the represented 1131 data. The results were considered significant at $P \le 0.05$.

1132

1133 **Reporting summary**

1134 Further information on research design is available in the Nature Research Reporting1135 Summary linked to this paper.

1136

Data and Materials availability:

Further information and requests for resources and reagents should be directed to Bhupesh K Prusty (<u>bhupesh.prusty@uni-wuerzburg.de</u>). The mass spectrometry proteomics data for the serum immunoglobulin proteome study have been deposited to the ProteomeXchange Consortium via the PRIDE partner repository with the dataset identifier PXD041945 and the same for HEK293 dUTPase co-IP proteome study with the dataset identifier PXD041942. All the experimental data are deposited to Mendley (doi: 10.17632/4xkft5g9r5.1).

1145 **References for Methods:**

- 11461Bahmer, T. *et al.* Severity, predictors and clinical correlates of Post-COVID syndrome1147(PCS) in Germany: A prospective, multi-centre, population-based cohort study.1148*EClinicalMedicine* **51**, 101549, doi:10.1016/j.eclinm.2022.101549 (2022).
- 11492Horn, A. et al. Long-term health sequelae and quality of life at least 6 months after1150infection with SARS-CoV-2: design and rationale of the COVIDOM-study as part of the1151NAPKON population-based cohort platform (POP). Infection 49, 1277-1287,1152doi:10.1007/s15010-021-01707-5 (2021).
- 11533Wagner, M. et al. Characteristics and Course of Heart Failure Stages A-B and1154Determinants of Progression design and rationale of the STAAB cohort study. Eur J1155Prev Cardiol 24, 468-479, doi:10.1177/2047487316680693 (2017).
- 11564Morbach, C. et al. Prevalence and determinants of the precursor stages of heart1157failure: results from the population-based STAAB cohort study. Eur J Prev Cardiol 28,1158924-934, doi:10.1177/2047487320922636 (2021).
- 11595Hennig, T. et al. Selective inhibition of miRNA processing by a herpesvirus-encoded1160miRNA. Nature 605, 539-544, doi:10.1038/s41586-022-04667-4 (2022).
- 11616Chowdhury, S. R. *et al.* Chlamydia preserves the mitochondrial network necessary for1162replication via microRNA-dependent inhibition of fission. J Cell Biol 216, 1071-1089,1163doi:10.1083/jcb.201608063 (2017).
- 11647Schindelin, J. et al. Fiji: an open-source platform for biological-image analysis. Nat1165Methods 9, 676-682, doi:10.1038/nmeth.2019 (2012).
- 11668Prusty, B. K., Chowdhury, S. R., Gulve, N. & Rudel, T. Peptidase Inhibitor 15 (PI15)1167Regulates Chlamydial CPAF Activity. Front Cell Infect Microbiol 8, 183,1168doi:10.3389/fcimb.2018.00183 (2018).
- 11699Gulve, N. et al. Anti-herpesviral effects of a novel broad range anti-microbial1170quaternary ammonium silane, K21. Antiviral Res131, 166-173,1171doi:10.1016/j.antiviral.2016.05.004 (2016).
- 117210Hughes, C. S. et al. Single-pot, solid-phase-enhanced sample preparation for1173proteomics experiments. Nat Protoc 14, 68-85, doi:10.1038/s41596-018-0082-x1174(2019).
- 117511Rappsilber, J., Ishihama, Y. & Mann, M. Stop and go extraction tips for matrix-assisted1176laser desorption/ionization, nanoelectrospray, and LC/MS sample pretreatment in1177proteomics. Anal Chem 75, 663-670, doi:10.1021/ac026117i (2003).
- 117812Cox, J. & Mann, M. MaxQuant enables high peptide identification rates,1179individualized p.p.b.-range mass accuracies and proteome-wide protein1180quantification. Nat Biotechnol 26, 1367-1372, doi:10.1038/nbt.1511 (2008).
- 118113Cox, J. et al. Accurate proteome-wide label-free quantification by delayed1182normalization and maximal peptide ratio extraction, termed MaxLFQ. Mol Cell1183Proteomics 13, 2513-2526, doi:10.1074/mcp.M113.031591 (2014).
- 1184 1185
- 1186

1187 **Extended Figure legends**:

1189 Extended Fig. 1: Herpesvirus reactivation in healthy population, ME/CFS, long COVID

1190 patients.

1188

- **a.** Demography of distribution of patients according to the age and gender.
- 1192 **b.** Likert chart showing percentage of positivity for antibodies against EBV, HSV-1 and HHV-6
- 1193 dUTPase within healthy controls (HC), ME/CFS, Covid-19 PCR positive but without long
- 1194 COVID (No LC), mild LC and severe LC patients. Kruskall Wallis (and its higher order
- 1195 equivalent, ScheirerRayHare Test) rank sum test for antibody state. HC, *P = 0.019; ME/CFS,
- 1196 *P = 0.021.
- 1197 Different amounts IgG levels in patient serum was arbitrarily divided into 4 groups (0,
- absent; 1, low; 2, moderate; 3, high).
- 1199

1200 Extended Fig. 2: Role of viral dUTPase proteins in mitochondrial dysfunction.

a. Confocal images showing hyperpolarization of mitochondria in U2-OS cells under transient

1202 expression of HSV-1, HHV-6 and EBV dUTPases. Mock vector was used as a control.

1203 **b**. Average mitochondrial surface area was compared between mock vector and EBV

1204 dUTPase transfected U2-OS cells. Data from three independent biological replicates. n=3.

- 1205 Unpaired two tailed non-parametric t-test. *P = 0.0278.
- 1206 **c.** Immunoblot analysis shows no major changes in dynamin related protein 1 (Drp1), p53,

1207 mitofusin1 (Mfn2), mitoguardin1 (Miga1) protein levels in presence of herpesvirus

1208 dUTPases. GAPDH staining was used as a loading control.

1209 **d.** TMRE dye was used to study mitochondrial membrane potential and OXPHOS in HEK293

- 1210 cells. Cells were transiently transfected with HHV-6, HSV-1 dUTPases or a mock vector for 48
- 1211 h. Non-transfected cells are also used as a control. Trypsinized cells were stained with TMRE

dye and were used for flow cytometry. Oligomycin was used to inhibit ATP synthase. Datafrom 3 independent experiments. n=3.

e. Data from above experiment was used to compare hyperpolarization status of
 mitochondria between mock transfected and EBV dUTPase transfected cells. Data from 3
 independent experiments. n=3.

f. Confocal images showing fragmentation of mitochondria in U2-OS cells in presence of recombinant EBV dUTPases. Same amounts of heat inactivated recombinant protein was used as a control. Average mitochondrial surface area was compared between control and recombinant EBV dUTPase exposed U2-OS cells. Data from four independent biological replicates. n=4. Unpaired two tailed non-parametric t-test. **P = 0.0032.

g. Immunoblot analysis shows upregulation of dynamin related protein 1 (Drp1) levels in U2-OS cells exposed to recombinant EBV dUTPase for 24 h in a dose dependent manner. GAPDH staining was used as a loading control. Drp1 levels are quantified from three independent biological replicates and are shown in the form of a scatter plot. n=3. Unpaired two tailed non-parametric t-test. 0 vs 2 µg, *P = 0.0229; 0 vs 5 µg, *P = 0.0360; 0 vs 10 µg, *P = 0.0201. **h.** TMRE dye was used to study mitochondrial membrane potential and OXPHOS in HEK293

1228 cells exposed to recombinant EBV dUTPase. Trypsinized cells were stained with TMRE dye

and were used for flow cytometry. Oligomycin was used to inhibit ATP synthase. Data from 3independent experiments. n=3.

i. Coomassie dye stained polyacrylamide gel with input and immunoprecipitated samples
 shows efficient pull down of Halo-tagged herpesvirus dUTPases. Potential protein bands co immunoprecipitated along with EBV and HSV-1 dUTPase protein is indicated.

1234 **j.** Normalized log2 ratio of LFQ (label-free quantitation) intensities of proteins. Fold change

- 1235 of proteins in EBV vs Mock was plotted against the same in HHV-6 vs Mock to highlight
- 1236 proteins that were specifically enriched in EBV dUTPase expressing co-IP.
- 1237 **k.** Normalized log2 ratio of LFQ (label-free quantitation) intensities of proteins. Fold change
- 1238 of proteins in HSV-1 vs Mock was plotted against the same in HHV-6 vs Mock to highlight
- 1239 proteins that were specifically enriched in HSV-1 dUTPase expressing co-IP.
- 1240 Circles indicate identified cellular proteins; circle size correlates with the number of peptides
- 1241 used for quantification. Significantly enriched proteins that are potential interaction partners
- 1242 of EBV (g) and HSV-1 (h) dUTPases are displayed in red.
- 1243 I. Immunoblot analysis to validate potential herpesvirus dUTPase interacting partners1244 identified from co-IP.
- 1245

1246 Extended Fig. 3: Immune modulations in ME/CFS.

a. Immunoblot analysis shows validation of enrichment IgG against EBV dUTPase within
purified IgG fractions. Recombinant dUTPase proteins are used as a bait. Left panel shows
specific detection of EBV dUTPase using an antibody raised against it. Middle panel shows
lack of specific signal against EBV dUTPase using a patient serum negative for EBV. Right
panel confirms the absence of the specific signal against EBV dUTPase within the purified
IgG. GAPDH staining was used as a loading control.

b. Immunoblot analysis shows positive validation of enrichment IgG against EBV dUTPase within purified IgG fractions. Recombinant dUTPase proteins are used as a bait. Left panel shows specific detection of EBV dUTPase using an antibody raised against it. Middle panel shows specific signal against EBV dUTPases using a EBV positive patient serum. Right panel

1257 confirms the presence of the specific signal against EBV dUTPase within the purified IgG.

1258 Desired band is indicated with an arrow. GAPDH staining was used as a loading control.

1259 c. A heat map of proteins identified by mass spectrometry within the purified
1260 immunoglobulin complexes. Each row represents a specific protein, and each column
1261 represents a specific patient sample. The lower panel of the heat map from upper panel is
1262 enlarged in the lower panel along with the protein names.

- d. Log10 values of normalized LFQ intensities of three altered proteins (serotrasferrin,
 alpha2 microglobulin and fibronectin) comparing healthy controls (n=12) with ME/CFS
 patients (n=15).
- 1266

1267 **Extended Fig. 4: Autoimmune signatures in ME/CFS.**

a. The Variables Factor map (Biplot) for the Principal Components (for patients and healthy

1269 Controls combined data) shows the projection of the top 10 Autoantigen variables projected

1270 onto the plane spanned by the first two Principal Components.

1271 **b**. Biplot of PCA analysis showing variation condensed to key dimensions (dim reduction) for

1272 the data set shown in Fig. 2e-f.

1273

1274 Extended Fig. 5: Circulating fibronectin in ME/CFS.

a. Immunoblot analysis shows overall increase in both plasma fibronectin (pIFN1) and cellular fibronectin (cIFN1) in ME/CFS patients. Equal amounts of serum proteins from 5 ME/CFS patients with higher serum fibronectin levels were run in parallel with the same from 5 healthy controls. Purified pIFN1, recombinant fibronectin isoform FN1.2 and HUVEC cell lysate expressing only cellular fibronectin were used as positive controls. Two different

1280 antibodies raised against Extra domain A (EDA) domain and CBD domain of fibronectin was

- used to differentiate plFN1 from clFN1 as plFN1 lacks EDA domain.
- 1282 **b.** Distribution of circulating FN1 concentrations in different groups of patients separated by
- 1283 gender. Two-tailed parametric t-test. Healthy control (HC) male vs female, **P = 0.0014; No
- LC male vs female, *P = 0.0204; severe LC male vs female, *P = 0.0347.
- 1285 c. Comparison of gender-specific circulating FN1 concentrations (log2 values) among
- 1286 different patient groups. Two-tailed parametric t-test. Healthy control (HC) male vs ME/CFS

1287 male, ***P = 0.0001; HC male vs mild LC male, *P = 0.012; HC female vs no LC female, *P =

- 1288 0.0193; HC female vs mild LC female, ***P = 0.0006; HC female vs severe LC female, **P =
- 1289 0.0016.

d. IgM antibody levels against fibronectin (FN1) in ME/CFS patients and healthy controls in the form of a violin plot. IgM levels were determined from microarray studies where each antigen was tested twice separately. Normalized values against signal to noise ratio and net fluorescence intensity is used.

e. Immunoblot analysis comparing the various species of circulating fibronectin (FN1) proteins in healthy controls and ME/CFS patient sera. Recombinant FN1.2 (recFN1.2) protein lacking extra domain-A (EDA domain) and HEK293 cell lysate serves as control. Three different antibodies detecting specific protein domains (EDA domain, CBD (cell binding domain) and cellular FN (clFN)) of FN1 was used against the same samples to compare the different species of proteins in the sera.

1300

1301 Extended Fig. 6: IgM-PC and IgM-MDA distributions among different groups of patients.

a. Distribution of serum IgM-PC concentrations in different groups of patients separated bygender.

- 1304 **b.** Distribution of serum IgM-MDA concentrations in different groups of patients separated
- 1305 by gender.

1306

1307 Extended Fig. 7: IgM-FN1 and IgG-FN1 distributions among different groups of patients.

- **a.** Distribution of serum IgM-FN1 concentrations in different groups of patients separated by
- 1309 gender. Two-tailed parametric t-test. ME/CFS male vs female, *P = 0.0398.
- 1310 **b.** Distribution of serum IgG-FN1 concentrations in different groups of patients separated by
- 1311 gender.
- 1312 c. Comparison of gender-specific IgM-FN1 concentrations (log2 values) among different
- 1313 patient groups. Two-tailed parametric t-test. Healthy control (HC) male vs No LC male, **P =

1314 0.003; HC male vs mild LC male, **P = 0.0018; HC male vs severe LC male, ***P = 0.0007; HC

- 1315 female vs no LC female, HC female vs mild LC female, HC female vs severe LC female, ****P
- 1316 < 0.0001.

1317

1318 Extended Fig. 8: Graphical abstract summarizing potential overlap between ME/CFS and

1319 long COVID pathogenesis.

1320 Both ME/CFS and long COVID possibly originates as a post viral illness. SARS-CoV-2 infection 1321 is the major infection behind long COVID. However, heightened reactivation of herpesviruses 1322 like HSV-1 and EBV can potentially play a role in development of ME/CFS. Similar increase in 1323 herpesvirus reactivations including those of HSV-1, HHV-6 and EBV are also observed in 1324 ME/CFS. Virus-induced direct changes in cellular physiology are expected to be the major 1325 driver for the disease development. Subsequently, chronic tissue inflammation could lead to 1326 changes in secondary tissue homeostasis where increase in circulating fibronectin levels can 1327 play a key role in TLR2/TLR4-mediated innate immune response, cytokine production,

1328	Platelet activation, mast cell activation and alterations in clot homeostasis. Major cellular
1329	alterations within primary and secondary hematopoietic tissues might lead to substantial
1330	decrease in natural IgM production, which subsequently drive the autoimmune feature of
1331	both ME/CFS and long COVID. Changed autoimmune signature in the form of autoantibodies
1332	could then cause mitochondrial dysfunction, endothelial cell damage initiating a vicious
1333	cycle of events that can lead to severe forms of both ME/CFS and long COVID.
1334	
1335	
1336	
1337	
1338	
1339	

1340

a Healthy controls ME/CFS 80-60-Mean Median 40-20-Age SARS-CoV-2 positive but no long COVID Mild long COVID Severe long COVID 80-. . . 60-40-























Fi	oronectin



d

Alpha2 Microglobulin











a











a Healthy controls ME/CFS 3000-. 2000-⊟ Mean Median 1000lgM-FN1 (ng/ml) 0-SARS-CoV-2 positive but no long COVID Mild long COVID Severe long COVID 3000-2000-













Site of chronic illness



Increased circulating Fibronectin as a result of chronic inflammation

Immunoglobulin-mediated endothelial cell alteration, Mitochondrial dysfunction, increased ROS **FN1**-induced TLR4 mediated pro-inflammatory cytokine response





茶

Chronic inflammation, Autoimmunity

Altered complement activation, Oppertunistic infections, Poor pathogen clearance Alterations in Gut microbiome

a 47.2 kDa 42.4 kDa 34.8 kDa



Tom20 Halo-dUTPase Mitofilin DAPI













